var title_f10_5_10320="Herpes simplex stromal keratitis";
var content_f10_5_10320=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex (HSV) stromal keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 422px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10320=[""].join("\n");
var outline_f10_5_10320=null;
var title_f10_5_10321="Diagram mortality predictors";
var content_f10_5_10321=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F83924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F83924&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 587px\">",
"   <div class=\"ttl\">",
"    Independent predictors for mortality in African children with severe malaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 567px; height: 610px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Venn diagram illustrating the combinations of presentations and associated mortality.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: von Seidlein L, Olaosebikan R, Hendriksen IC, et al. Predicting the clinical outcome of severe falciparum malaria in African children: Findings from a large randomized trial. Clin Infect Dis 2012; 54:1080. By permission of the Infectious Diseases Society of America. Copyright &copy; 2012 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10321=[""].join("\n");
var outline_f10_5_10321=null;
var title_f10_5_10322="Carcinoid tumor appendix";
var content_f10_5_10322=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Appendiceal carcinoid tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathologic specimen of a carcinoid tumor of the distal appendix (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen E Goldfinger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10322=[""].join("\n");
var outline_f10_5_10322=null;
var title_f10_5_10323="Atrial fibrillation WPW";
var content_f10_5_10323=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Episode of atrial fibrillation with rapid conduction to the ventricle via the accessory pathway in patient with Wolff-Parkinson-White syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 236px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10323=[""].join("\n");
var outline_f10_5_10323=null;
var title_f10_5_10324="Peyronies disease plaque cross section";
var content_f10_5_10324=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F61965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F61965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Dorsal Peyronies disease plaque on penile cross-section",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 400px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The tunica albuginea is a tough layer of fibrous connective tissue surrounding the corpora cavernosa and corpus spongiosum of the penis. Plaque in Peyronie's disease can form in the dorsal (as shown above), ventral, or lateral portions of the penis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10324=[""].join("\n");
var outline_f10_5_10324=null;
var title_f10_5_10325="Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors";
var content_f10_5_10325=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical trials of HIV antiretroviral therapy: Triple regimens using nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10325/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10325/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10325/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10325/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10325/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10325/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/5/10325/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;During the past decade, a greater understanding of the optimal approaches to HIV treatment has evolved. From the beginning of the era of potent antiretroviral therapy, nucleoside analogs have played a prominent role as part of combination treatment strategies. Even after the development of drugs from different classes, an interest arose in a single-class approach using nucleoside analogs alone. Potential benefits of this approach included simplicity of treatment, lower cost, fewer drug-drug interactions, and sparing other drug classes for future use.",
"   </p>",
"   <p>",
"    This topic will describe trials that evaluated the efficacy and safety of three-drug combination nucleoside analog therapy for treatment-naive patients. Early clinical trials evaluating dual versus single nucleoside analog therapy and drug resistance issues are discussed elsewhere. Use of nucleoside analogs as part of a combination regimen with other drug classes is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=see_link\">",
"     \"Primer on interpretation of HIV drug resistance testing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=see_link\">",
"     \"Clinical trials of HIV antiretroviral therapy: Integrase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    (ZDV; also known as AZT) was the first nucleoside analog to be approved for the treatment of HIV infection in 1987. ZDV monotherapy led to only transient clinical and immunologic improvements. Subsequent clinical monotherapy trials using other nucleoside analogs led to only slightly better results. The major breakthrough in clinical management of HIV infection came with the first clinical trial that demonstrated the benefit of three-drug therapy, which included two different classes of antiretroviral drugs.",
"   </p>",
"   <p>",
"    Subsequently, interest grew in designing treatment regimens using three drugs from the NRTI class. The potential potency of these regimens was supported by in vitro studies demonstrating additive and sometimes synergistic activity when these drugs were combined. It was furthermore hoped that this \"class-sparing\" approach would help avoid some of the toxicities of other drugs (eg, hypertriglyceridemia associated with many protease inhibitors) and to preserve future drug treatment options. Coformulations of nucleoside analogs became available, which decreased pill burden and dosing frequency and were thus an attractive option for this treatment strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Abbreviations used",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abbreviations used in this topic include ZDV (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    ; also known as AZT), d4T (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ), ddI (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    ), 3TC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ), FTC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ), ABC (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    ) and TDF (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    ); one of the earliest nucleoside analogs, zalcitabine (ddC), was withdrawn from the market.",
"   </p>",
"   <p>",
"    Some trials utilizing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , a nonnucleoside reverse transcriptase inhibitor, are also discussed below. Efavirenz (EFV) is also known as Sustiva.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     STUDIES OF THREE OR MORE NRTIs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Zidovudine plus lamivudine plus abacavir (ACTG A5095)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial trial data suggested that",
"    <span class=\"nowrap\">",
"     ZDV/3TC/ABC",
"    </span>",
"    triple nucleoside analog therapy was equivalent in efficacy compared to ART regimens employing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. However, a consistent finding in these studies was a higher rate of treatment failure in those patients with higher baseline HIV RNA levels who received",
"    <span class=\"nowrap\">",
"     ZDV/3TC/ABC.",
"    </span>",
"    This finding raised concern over the lower potency of this combination compared to PI-containing regimens.",
"   </p>",
"   <p>",
"    Subsequently, the",
"    <span class=\"nowrap\">",
"     ZDV/3TC/ABC",
"    </span>",
"    triple nucleoside analog strategy was compared with",
"    <span class=\"nowrap\">",
"     ZDV/3TC",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , and",
"    <span class=\"nowrap\">",
"     ZDV/3TC/ABC",
"    </span>",
"    plus efavirenz in a randomized, double blind study (AIDS Clinical Trial Group; ACTG 5095) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/3\">",
"     3",
"    </a>",
"    ]. A total of 1147 subjects with a mean baseline HIV-1 RNA level of 4.85 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and a mean CD4 count of 238",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    were enrolled.",
"   </p>",
"   <p>",
"    After a median follow-up of 32 weeks, the triple NRTI arm of the study was stopped by the monitoring board. In an analysis that combined the two EFV-containing arms, virologic failure was more common in patients receiving only",
"    <span class=\"nowrap\">",
"     ABC/3TC/ZDV",
"    </span>",
"    (21 versus 11 percent) and time to virologic failure was shorter.",
"   </p>",
"   <p>",
"    A substudy (ACTG 5166) was designed to evaluate plasma HIV-1 RNA decay rates in 66 study participants in the three different treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/4\">",
"     4",
"    </a>",
"    ]. Median first-phase viral decay rates at day 10 were significantly faster in subjects receiving the three-drug EFV regimen compared with those receiving the triple-nucleoside regimen; these differences were even more pronounced in patients with higher baseline viral loads. These data suggest that early viral dynamic modeling may be a useful tool in predicting treatment efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Abacavir plus lamivudine plus tenofovir (ESS30009 Study)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized, open-label, multicenter study compared TDF versus EFV, both administered once daily with the",
"    <span class=\"nowrap\">",
"     ABC/3TC",
"    </span>",
"    fixed-dose combination in 340 treatment-naive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/6\">",
"     6",
"    </a>",
"    ]. The median baseline HIV-1 RNA level was 4.7 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and the CD4 count was 251",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    This",
"    trial was stopped early after an interim analysis demonstrated that patients in the",
"    <span class=\"nowrap\">",
"     ABC/3TC/TDF",
"    </span>",
"    arm had a much higher rate of virologic nonresponse than the comparator arm (49 versus 5 percent). Within 12 weeks, high rates of the M184V (98 percent) and K65R (54 percent) resistance mutations were seen in virologic nonresponders in the",
"    <span class=\"nowrap\">",
"     ABC/3TC/TDF",
"    </span>",
"    arm. Similar results were seen in another pilot study [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors suggested that a low genetic barrier to resistance, produced by synergistic selection pressure from all three drugs, may have contributed to these findings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/6\">",
"     6",
"    </a>",
"    ]. However, only half of the patients developed the K65R mutation; furthermore, the M184V by itself actually sensitizes HIV to TDF and has only a modest effect on ABC susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/8\">",
"     8",
"    </a>",
"    ]. An alternative explanation for the high virologic failure rates and resistance patterns include differential drug localization in various cellular compartments [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the cause, the surprisingly poor antiviral effect of the",
"    <span class=\"nowrap\">",
"     ABC/3TC/TDF",
"    </span>",
"    arm highlights the limitations of using unstudied combinations of antiretrovirals in clinical practice, even when each individual agent is likely to be fully active.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lamivudine plus didanosine plus tenofovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 24-week pilot study was performed in 22 treatment-naive patients using triple nucleoside analog therapy with 3TC plus ddI and TDF [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/9\">",
"     9",
"    </a>",
"    ]. The baseline mean viral load was 4.9 log(10)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and the mean CD4 count was 133 cells.",
"   </p>",
"   <p>",
"    After 12 weeks of treatment only 1 of 22 patients had a virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/9\">",
"     9",
"    </a>",
"    ]. Of 20 patients who had resistance testing, all had developed the M184V resistance mutation and 10 had the K65R resistance mutation. One study has suggested that the level of drug resistance may be underestimated by phenotypic testing when mixtures of wild-type and drug-resistant virus are present [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/10\">",
"     10",
"    </a>",
"    ]. This issue is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=see_link\">",
"     \"Overview of HIV drug resistance testing assays\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=see_link\">",
"     \"Drug resistance testing in the clinical management of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Tenofovir-emtricitabine plus zidovudine plus abacavir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three hundred twenty-two treatment-naive, HLA-B*5701-negative patients were randomized to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/52/1863?source=see_link\">",
"     tenofovir-emtricitabine",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    , ritonavir-boosted",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10325/abstract/11\">",
"     11",
"    </a>",
"    ]. The quadruple NRTI regimen was less effective in achieving virologic suppression at week 48 and was associated with more serious adverse events and a greater degree of lipoatrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, studies of three or four nucleoside analog regimens demonstrate inferior antiviral activity compared to two-class regimens containing NRTIs plus a drug from a different class. Furthermore, treatment with some triple nucleoside analog regimens (notably",
"    <span class=\"nowrap\">",
"     ABC/3TC/TDF",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     ddI/3TC/TDF)",
"    </span>",
"    was associated with a very high risk of developing drug resistance mutations. For these reasons, treatment with triple NRTIs as initial therapy should generally be avoided, unless PIs or NNRTIs cannot be used.",
"   </p>",
"   <p>",
"    Even under these circumstances, the availability of newer agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     raltegravir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    , provide treatment options that are likely to be more effective than triple NRTI-based therapy. In the event that such triple NRTI therapy is required, however, the recommended regimen should be",
"    <span class=\"nowrap\">",
"     ZDV/3TC/ABC.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Interest in NRTI-only-based combination regimens arose from observations of synergistic activity in vitro. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional potential benefits of this \"class sparing\" approach include a relative lack of drug-drug interactions, low cost, and preservation of future treatment options in the event of virologic failure. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment studies with",
"      <span class=\"nowrap\">",
"       ZDV/3TC/ABC",
"      </span>",
"      have generally shown inferior antiviral activity compared with regimens containing two NRTIs plus either a PI or EFV. This observation has been particularly notable in patients with baseline high HIV RNA levels.",
"     </li>",
"     <li>",
"      Regimens using",
"      <span class=\"nowrap\">",
"       ABC/3TC/TDF",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       ddI/3TC/TDF",
"      </span>",
"      are associated with a high risk of early virologic failure and high rates of resistance; as such, they should not be used for treatment.",
"     </li>",
"     <li>",
"      Based on the above study results, regimens containing only NRTIs are not recommended unless two class regimens are contraindicated. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Studies of three or more NRTIs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/1\">",
"      Staszewski S, Keiser P, Montaner J, et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 2001; 285:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/2\">",
"      Kumar PN, Rodriguez-French A, Thompson MA, et al. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity. HIV Med 2006; 7:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/3\">",
"      Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/4\">",
"      Kuritzkes DR, Ribaudo HJ, Squires KE, et al. Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s. J Infect Dis 2007; 195:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/5\">",
"      Markowitz M, Perelson AS. HIV-1 viral dynamics studies in the setting of clinical trials--A window of opportunity. J Infect Dis 2007; 195:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/6\">",
"      Gallant JE, Rodriguez AE, Weinberg WG, et al. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J Infect Dis 2005; 192:1921.",
"     </a>",
"    </li>",
"    <li>",
"     Landman R, Peytavin G, Descamps D, et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: The Tonus study. 11th Conference on Retroviruses and Opportunstic Infections, February 2004, San Francisco.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/8\">",
"      Kuritzkes DR. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen. J Infect Dis 2005; 192:1867.",
"     </a>",
"    </li>",
"    <li>",
"     Jemsek J, Hutcherson P, Harper E. Poor virologic responses and early emergence of resistance in treatment-naive, HIV-infected patients receiving a once-daily triple nucleoside regimen of didanosine, lamivudine, and tenofovir DF. 11th Conference on Retroviruses and Opportunstic Infections, February 2004, San Francisco.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10325/abstract/10\">",
"      Underwood MR, Ross LL, Irlbeck DM, et al. Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. J Infect Dis 2009; 199:84.",
"     </a>",
"    </li>",
"    <li>",
"     Cooper DA. Safety and efficacy of three different combination antiretroviral regimens as initial therapy for HIV infection: week 48 data from a randomised, open-label study. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 19-22 July 2009. Abstract LBPEB09.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3791 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-39486C3A7C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10325=[""].join("\n");
var outline_f10_5_10325=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Abbreviations used",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      STUDIES OF THREE OR MORE NRTIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Zidovudine plus lamivudine plus abacavir (ACTG A5095)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Abacavir plus lamivudine plus tenofovir (ESS30009 Study)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lamivudine plus didanosine plus tenofovir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Tenofovir-emtricitabine plus zidovudine plus abacavir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11286?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Early clinical trials (1987 to 1996)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/34/7720?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Integrase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9287?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Non-nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/16/17672?source=related_link\">",
"      Clinical trials of HIV antiretroviral therapy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32424?source=related_link\">",
"      Drug resistance testing in the clinical management of HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/48/4873?source=related_link\">",
"      Overview of HIV drug resistance testing assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/26/34218?source=related_link\">",
"      Primer on interpretation of HIV drug resistance testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_5_10326="Home sleep tracing";
var content_f10_5_10326=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77569&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Home sleep tracing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical tracing from a 4 channel cardiopulmonary recording performed at home. The parameters measured include pulse rate, chest wall impedance, airflow, and oxygen saturation. Obstructive apneas are denoted by the letter A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10326=[""].join("\n");
var outline_f10_5_10326=null;
var title_f10_5_10327="Protriptyline: Drug information";
var content_f10_5_10327=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Protriptyline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39876?source=see_link\">",
"    see \"Protriptyline: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44550?source=see_link\">",
"    see \"Protriptyline: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F215269\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vivactil&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F215285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidepressant, Tricyclic (Secondary Amine)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F215272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: 15-60 mg/day in 3-4 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F215278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44550?source=see_link\">",
"      see \"Protriptyline: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Depression:",
"     </b>",
"     Oral: Adolescents: 15-20 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F215273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Initial: 5-10 mg/day; increase every 3-7 days by 5-10 mg; usual dose: 15-20 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F215248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg, 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vivactil&reg;: 5 mg, 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F215233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089820.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089820.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F215253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Make any dosage increase in the morning dose",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F215252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of depression",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F4425704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vivactil&reg; may be confused with Vyvanse&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (SIADH: Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F215283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmias, heart block, hyper-/hypotension, MI, palpitation, stroke, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, ataxia, confusion, delirium, delusions, dizziness, drowsiness, EPS, exacerbation of psychosis, fatigue, hallucinations, headache, hypomania, incoordination, insomnia, nightmares, panic, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, itching, petechiae, photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement, galactorrhea, gynecomastia, increased or decreased libido, syndrome of inappropriate ADH secretion (SIADH)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, decreased lower esophageal sphincter tone may cause GE reflux, diarrhea, heartburn, increased appetite, nausea, trouble with gums, unpleasant taste, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, impotence, testicular edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, increased liver enzymes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Fine muscle tremor, numbness, tingling, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, eye pain, increased intraocular pressure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, excessive diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F215256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to protriptyline (cross-reactivity to other cyclic antidepressants may occur) or any component of the formulation; use of MAO inhibitors within 14 days; use of cisapride; use in a patient during the acute recovery phase of MI",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F215237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Protriptyline is FDA approved for the treatment of depression in adolescents.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems. The degree of anticholinergic blockade produced by this agent is moderate relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: TCAs may rarely cause bone marrow suppression; monitor for any signs of infection and obtain CBC if symptoms (eg, fever, sore throat) evident.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension (risk is moderate relative to other antidepressants); use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation: May cause sedation, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). The degree of sedation is low relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with a history of cardiovascular disease (including previous MI, stroke, tachycardia, or conduction abnormalities); the risk conduction abnormalities with this agent is moderate-high relative to other antidepressants.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose regulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: May aggravate aggressive behavior or worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Protriptyline is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with hyperthyroidism or those receiving thyroid supplementation due to concerns of pro-arrhythmogenesis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic and/or neuroleptic agents: Hyperpyrexia has been observed with TCAs in combination with anticholinergics and/or neuroleptics, particularly during hot weather.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in elderly patients; may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults. May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Recommended to discontinue prior to elective surgery requiring general anesthesia. Therapy should not be abruptly discontinued in patients receiving high doses for prolonged periods.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electroconvulsive therapy: May increase the risks associated with electroconvulsive therapy; consider discontinuing, when possible, prior to ECT treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F215281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F215242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Tricyclic Antidepressants may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Tricyclic Antidepressants may enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: Tricyclic Antidepressants may diminish the antihypertensive effect of Alpha2-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Tricyclic Antidepressants may enhance the stimulatory effect of Amphetamines. Tricyclic Antidepressants may also potentiate the cardiovascular effects of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Tricyclic Antidepressants may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cinacalcet: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protriptyline may enhance the arrhythmogenic effect of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Tricyclic Antidepressants may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Dexmethylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DULoxetine: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Tricyclic Antidepressants may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: May enhance the serotonergic effect of Tricyclic Antidepressants. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: May enhance the neurotoxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: Tricyclic Antidepressants may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Tricyclic Antidepressants. Management: Seek alternatives to this combination when possible. Monitor patients receiving metoclopramide with tricyclic antidepressants for signs of extrapyramidal symptoms, neuroleptic malignant syndrome, and serotonin syndrome.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Tricyclic Antidepressants may enhance the QTc-prolonging effect of QuiNIDine. QuiNIDine may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Tricyclic Antidepressants may enhance the adverse/toxic effect of Sodium Phosphates. Specifically, the risk of seizure and/or loss of consciousness may be increased in patients with significant sodium phosphate induced fluid/electrolyte abnormalities.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Tricyclic Antidepressants. The risk of serotonin syndrome may theoretically be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Cyclic Antidepressants may enhance the hypoglycemic effect of Sulfonylureas.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Terbinafine (Systemic): May decrease the metabolism of Tricyclic Antidepressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: Tricyclic Antidepressants may enhance the neuroexcitatory and/or seizure-potentiating effect of TraMADol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: May increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tricyclic Antidepressants may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: Tricyclic Antidepressants may increase the serum concentration of Yohimbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F215265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may inhibit the metabolism of some TCAs and clinical toxicity may result.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, SAMe, kava kava (may increase risk of serotonin syndrome and/or excessive sedation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13447521\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F215275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F215258\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Protriptyline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $211.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $306.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Vivactil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $366.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $531.24",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F215245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for cardiac abnormalities in elderly patients receiving doses &gt;20 mg; suicide ideation (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F215249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Therapeutic: 70-250 ng/mL (SI: 266-950 nmol/L); Toxic: &gt;500 ng/mL (SI: &gt;1900 nmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Concordin (DK, GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F215236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increases the synaptic concentration of serotonin and/or norepinephrine in the central nervous system by inhibition of their reuptake by the presynaptic neuronal membrane",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F215255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses placenta",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 92%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via N-oxidation, hydroxylation, and glucuronidation; first-pass effect (10% to 25%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 54-92 hours (average: 74 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 24-30 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boakes AJ, Laurence DR, Teoh PC, et al, &ldquo;Interactions Between Sympathomimetic Amines and Antidepressant Agents in Man,&rdquo;",
"      <i>",
"       Br Med J",
"      </i>",
"      , 1973, 1(849):311-5.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jastak JT and Yagiela JA, &ldquo;Vasoconstrictors and Local Anesthesia: A Review and Rationale for Use,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1983, 107(4):623-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/6355236/pubmed\" id=\"6355236\" target=\"_blank\">",
"        6355236",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Larochelle P, Hamet P, and Enjalbert M, &ldquo;Responses to Tyramine and Norepinephrine After Imipramine and Trazodone,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1979, 26(1):24-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/376211/pubmed\" id=\"376211\" target=\"_blank\">",
"        376211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mitchell JR, &ldquo;Guanethidine and Related Agents. III Antagonism by Drugs Which Inhibit the Norepinephrine Pump in Man,&rdquo;",
"      <i>",
"       J Clin Invest",
"      </i>",
"      , 1970, 49(8):1596-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/5431666/pubmed\" id=\"5431666\" target=\"_blank\">",
"        5431666",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nelson JC and Devanand DP, \"A Systematic Review and Meta-Analysis of Placebo-Controlled Antidepressant Studies in People With Depression and Dementia,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2011, 59(4):577-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/21453380/pubmed\" id=\"21453380\" target=\"_blank\">",
"        21453380",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass SE and Simpson RW, &ldquo;Discontinuation and Reinstitution of Medications During the Perioperative Period,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2004, 61(9):899-912.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/15156966/pubmed\" id=\"15156966\" target=\"_blank\">",
"        15156966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Roose SP, Glassman AH, Attia E, et al, &ldquo;Comparative Efficacy of Selective Serotonin Reuptake Inhibitors and Tricyclics in the Treatment of Melancholia,&rdquo;",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 1994, 151(12):1735-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/7977878/pubmed\" id=\"7977878\" target=\"_blank\">",
"        7977878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rundegren J, van Dijken J, M&ouml;rnstad H, et al, &ldquo;Oral Conditions in Patients Receiving Long-Term Treatment With Cyclic Antidepressant Drugs,&rdquo;",
"      <i>",
"       Swed Dent J",
"      </i>",
"      , 1985, 9(2):55-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10327/abstract-text/3925584/pubmed\" id=\"3925584\" target=\"_blank\">",
"        3925584",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Svedmyr N, &ldquo;The Influence of a Tricyclic Antidepressive Agent (Protriptyline) on Some of the Circulatory Effects of Noradrenaline and Adrenalin in Man,&rdquo;",
"      <i>",
"       Life Sci",
"      </i>",
"      , 1968, 7(1):77-84.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9832 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10327=[""].join("\n");
var outline_f10_5_10327=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709377\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215269\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215285\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215272\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215278\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215273\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215248\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215233\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874824\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215253\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215252\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4425704\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215283\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215256\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215237\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215281\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215242\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215265\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13447521\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215275\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215258\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215245\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215249\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038790\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215236\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F215255\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9832\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9832|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?38/60/39876?source=related_link\">",
"      Protriptyline: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/32/44550?source=related_link\">",
"      Protriptyline: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_5_10328="Acetaminophen and codeine: Drug information";
var content_f10_5_10328=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Acetaminophen and codeine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24005?source=see_link\">",
"    see \"Acetaminophen and codeine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/12/5319?source=see_link\">",
"    see \"Acetaminophen and codeine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F14854545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Warns of Codeine Use in Children After Tonsillectomy and/or Adenoidectomy",
"     </span>",
"     <span class=\"collapsible-date\">",
"      August 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The FDA has issued a Drug Safety Communication after reviewing reports of children who developed serious adverse effects, including death, after receiving codeine in the usual dosage range for pain relief following tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. Three deaths occurred in children that had evidence of a genetic variation (&ldquo;ultrarapid metabolizers&rdquo;) which results in faster and more complete conversion of codeine to morphine, possibly leading to overdose or death. The estimated incidence of this genetic variation is ~1-7 per 100 people, but may be higher in some ethnic groups.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Healthcare professionals should be aware of the risks associated with the administration of codeine or codeine-containing drugs in children after tonsillectomy and/or adenoidectomy for obstructive sleep apnea and should use the lowest effective dose for the least amount of time on an as-needed basis. Parents and caregivers who observe signs of overdose in a child such as unusual sleepiness, confusion, or difficult or noisy breathing should stop codeine administration and seek medical attention immediately.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information may be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm313631.htm#",
"       </a>",
"       .",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F13114313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F129491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capital&reg; and Codeine;",
"     </li>",
"     <li>",
"      Tylenol&reg; with Codeine No. 3;",
"     </li>",
"     <li>",
"      Tylenol&reg; with Codeine No. 4",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F129492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      ratio-Emtec;",
"     </li>",
"     <li>",
"      ratio-Lenoltec;",
"     </li>",
"     <li>",
"      Triatec-30;",
"     </li>",
"     <li>",
"      Triatec-8;",
"     </li>",
"     <li>",
"      Triatec-8 Strong;",
"     </li>",
"     <li>",
"      Tylenol Elixir with Codeine;",
"     </li>",
"     <li>",
"      Tylenol No. 1;",
"     </li>",
"     <li>",
"      Tylenol No. 1 Forte;",
"     </li>",
"     <li>",
"      Tylenol No. 2 with Codeine;",
"     </li>",
"     <li>",
"      Tylenol No. 3 with Codeine;",
"     </li>",
"     <li>",
"      Tylenol No. 4 with Codeine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F129510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Analgesic Combination (Opioid)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F129493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be adjusted according to severity of pain and response of the patient. Adult doses &ge;60 mg codeine fail to give commensurate relief of pain but merely prolong analgesia and are associated with an appreciably increased incidence of side effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Cough (Antitussive):",
"     </b>",
"     Oral: Based on codeine (15-30 mg/dose) every 4-6 hours (maximum: 360 mg/24 hours based on codeine component)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pain (Analgesic):",
"     </b>",
"     Oral: Based on codeine (30-60 mg/dose) every 4-6 hours (maximum: 4000 mg/24 hours based on acetaminophen component)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-2 tablets every 4 hours to a maximum of 12 tablets/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F129503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/12/5319?source=see_link\">",
"      see \"Acetaminophen and codeine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Analgesic:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Codeine: 0.5-1 mg codeine/kg/dose every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acetaminophen: 10-15 mg/kg/dose every 4 hours up to a maximum of 2.6 g/24 hours for children &lt;12 years; alternatively, the following can be used:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      3-6 years:",
"     </i>",
"     5 mL 3-4 times/day as needed of elixir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      7-12 years:",
"     </i>",
"     10 mL 3-4 times/day as needed of elixir",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Children &gt;12 years:",
"     </i>",
"     15 mL every 4 hours as needed of elixir",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F129494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Doses should be titrated to appropriate analgesic effect.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     One Tylenol&reg; No. 3 tablet every 4 hours; do",
"     <b>",
"      not",
"     </b>",
"     exceed 4 g/day acetaminophen.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F129495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F129496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution. Limited, low-dose therapy is usually well tolerated in hepatic disease/cirrhosis; however, cases of hepatotoxicity at daily acetaminophen dosages &lt;4 g/day have been reported. Avoid chronic use in hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F129479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral [C-V]: Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL (5 mL, 10 mL, 12.5 mL, 15 mL, 120 mL, 480 mL) [contains alcohol 7%]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral [C-V] (Capital&reg; and Codeine): Acetaminophen 120 mg and codeine phosphate 12 mg per 5 mL (480 mL) [alcohol free; contains propylene glycol, sodium benzoate; fruit punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [C-III]: Acetaminophen 300 mg and codeine phosphate 15 mg; acetaminophen 300 mg and codeine phosphate 30 mg; acetaminophen 300 mg and codeine phosphate 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; with Codeine No. 3: Acetaminophen 300 mg and codeine phosphate 30 mg [contains sodium metabisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol&reg; with Codeine No. 4: Acetaminophen 300 mg and codeine phosphate 60 mg [contains sodium metabisulfite]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8119602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"     <b>",
"      Note:",
"     </b>",
"     In countries outside of the U.S., some formulations of Tylenol&reg; with Codeine include caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ratio-Lenoltec No. 1, Tylenol No. 1: Acetaminophen 300 mg, codeine phosphate 8 mg, and caffeine 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol No. 1 Forte: Acetaminophen 500 mg, codeine phosphate 8 mg, and caffeine 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tylenol Elixir with Codeine: Acetaminophen 160 mg and codeine phosphate 8 mg per 5 mL (500 mL) [contains alcohol 7%, sucrose 31%; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ratio-Emtec, Triatec-30: Acetaminophen 300 mg and codeine phosphate 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ratio-Lenoltec No. 1: Acetaminophen 300 mg, codeine phosphate 8 mg, and caffeine 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ratio-Lenoltec No. 2, Tylenol No. 2 with Codeine: Acetaminophen 300 mg, codeine phosphate 15 mg, and caffeine 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ratio-Lenoltec No. 3, Tylenol No. 3 with Codeine: Acetaminophen 300 mg, codeine phosphate 30 mg, and caffeine 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ratio-Lenoltec No. 4, Tylenol No. 4 with Codeine: Acetaminophen 300 mg and codeine phosphate 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triatec-8: Acetaminophen 325 mg, codeine phosphate 8 mg, and caffeine 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triatec-8 Strong: Acetaminophen 500 mg, codeine phosphate 8 mg, and caffeine 30 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F129463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F129512\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III; C-V",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9378368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F129481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of mild-to-moderate pain",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F129518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tylenol&reg; may be confused with atenolol, timolol, Tylox&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Duplicate therapy issues: This product contains acetaminophen, which may be a component of other combination products. Do not exceed the maximum recommended daily dose of acetaminophen.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       T3 is an error-prone abbreviation (mistaken as liothyronine)",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Codex: Brand name for acetaminophen/codeine [Brazil], but also the brand name for",
"       <i>",
"        saccharomyces boulardii",
"       </i>",
"       [Italy]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Codex [Brazil] may be confused with Cedax brand name for ceftibuten [U.S. and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F129508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness, lightheadedness, sedation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dysphonia, euphoria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Histamine release",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Antidiuretic hormone release, biliary tract spasm, bradycardia, hypotension, intracranial pressure increased, miosis, palpitation, peripheral vasodilation, physical and psychological dependence, respiratory depression, urinary retention",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F129484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to acetaminophen, codeine, or any component of the formulation; significant respiratory depression (in unmonitored settings); acute or severe bronchial asthma; hypercapnia; paralytic ileus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F129467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatotoxicity:",
"     <b>",
"      [U.S. Boxed Warning]: Acetaminophen may cause severe hepatotoxicity, potentially requiring liver transplant or resulting in death; hepatotoxicity is usually associated with excessive acetaminophen intake (&gt;4 g/day).",
"     </b>",
"     Risk is increased with alcohol use, pre-existing liver disease, and intake of more than one source of acetaminophen-containing medications. Chronic daily dosing in adults has also resulted in liver damage in some patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/anaphylactic reactions: Hypersensitivity and anaphylactic reactions have been reported with acetaminophen use; discontinue immediately if symptoms of allergic or hypersensitivity reactions occur. Use with caution in patients with hypersensitivity reactions to other phenanthrene-derivative opioid agonists (hydrocodone, hydromorphone, levorphanol, oxycodone, oxymorphone).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: May cause hypotension; use with caution in patients with hypovolemia, cardiovascular disease (including acute MI), or drugs which may exaggerate hypotensive effects (including phenothiazines or general anesthetics).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abdominal conditions: May obscure diagnosis or clinical course of patients with acute abdominal conditions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal insufficiency: Use with caution in patients with adrenal insufficiency, including Addison's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression/coma: Use with caution in patients with CNS depression or coma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Use with caution in patients with alcoholic liver disease; consuming &ge;3 alcoholic drinks/day may increase the risk of liver damage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Head trauma: Use with extreme caution in patients with head injury, intracranial lesions, or elevated intracranial pressure; exaggerated elevation of ICP may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with severe hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary stricture: Use with caution in patients with prostatic hyperplasia and/or urinary stricture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with pre-existing respiratory compromise (hypoxia and/or hypercapnia), COPD or other obstructive pulmonary disease, and kyphoscoliosis or other skeletal disorder which may alter respiratory function; critical respiratory depression may occur, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CYP2D6 &ldquo;ultrarapid metabolizers&rdquo;: Use caution in patients with two or more copies of the variant CYP2D6*2 allele; may have extensive conversion to morphine and thus increased opioid-mediated effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in debilitated patients; there is a greater potential for critical respiratory depression, even at therapeutic dosages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; may be more sensitive to adverse effects. Decrease initial dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metabisulfite: Tablets contain metabisulfite which may cause allergic reactions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Non-U.S. formulations: Some non-U.S. formulations (including most Canadian formulations) may contain caffeine as an additional ingredient. Caffeine may cause CNS and cardiovascular stimulation, as well as GI irritation in high doses. Use with caution in patients with a history of peptic ulcer or GERD; avoid in patients with symptomatic cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage limit: Limit acetaminophen dose from all sources (prescription and OTC) to &lt;4 g/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Withdrawal: Concurrent use of agonist/antagonist analgesics may precipitate withdrawal symptoms and/or reduced analgesic efficacy  in patients following prolonged therapy with mu opioid agonists. Abrupt discontinuation following prolonged use may also lead to withdrawal symptoms.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F129504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F129472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alvimopan: Analgesics (Opioid) may enhance the adverse/toxic effect of Alvimopan. This is most notable for patients receiving long-term (i.e., more than 7 days) opiates prior to alvimopan initiation.  Management: Alvimopan is contraindicated in patients receiving therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan initiation.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ammonium Chloride: May increase the excretion of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May enhance the analgesic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticonvulsants (Hydantoin): May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Acetaminophen may increase the serum concentration of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Acetaminophen. This may 1) diminish the effect of acetaminophen; and 2) increase the risk of liver damage.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholestyramine Resin: May decrease the absorption of Acetaminophen. Effect is minimal if cholestyramine is administered 1 hour after acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Acetaminophen may enhance the hepatotoxic effect of Dasatinib. Dasatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Analgesics (Opioid) may enhance the adverse/toxic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Acetaminophen may enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May enhance the adverse/toxic effect of Acetaminophen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrapone: May increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Acetaminophen may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mixed Agonist / Antagonist Opioids: May diminish the analgesic effect of Analgesics (Opioid). Management: Seek alternatives to mixed agonist/antagonist opioids in patients receiving pure opioid agonists, and monitor for symptoms of therapeutic failure/high dose requirements (or withdrawal in opioid-dependent patients) if patients receive these combinations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: Analgesics (Opioid) may diminish the therapeutic effect of Pegvisomant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Acetaminophen. Probenecid may also limit the formation of at least one major non-toxic metabolite, possibly increasing the potential for formation of the toxic NAPQI metabolite.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: Analgesics (Opioid) may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatostatin Analogs: May decrease the metabolism of Codeine. The formation of two major codeine metabolites (morphine and norcodeine) may be impaired by somatostatin analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Acetaminophen may enhance the hepatotoxic effect of SORAfenib. SORAfenib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: May enhance the bradycardic effect of Analgesics (Opioid).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Analgesics (Opioid) may enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Acetaminophen may enhance the anticoagulant effect of Vitamin K Antagonists. Most likely with daily acetaminophen doses &gt;1.3 g for &gt;1 week.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F129489\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Excessive intake of ethanol may increase the risk of acetaminophen-induced hepatotoxicity. Avoid ethanol or limit to &lt;3 drinks/day.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F129473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5182920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F129498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5182922\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F129486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F2524294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Acetaminophen-Codeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120-12 mg/5 mL (473 mL): $18.75",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Capital/Codeine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120-12 mg/5 mL (473 mL): $607.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol with Codeine #3 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-30 mg (100): $105.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Tylenol with Codeine #4 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300-60 mg (100): $187.21",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F129476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of pain, respiratory and mental status, blood pressure, bowel function",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F129487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Algimide (CO);",
"     </li>",
"     <li>",
"      Algimide F (CO);",
"     </li>",
"     <li>",
"      An Du Fen (CL);",
"     </li>",
"     <li>",
"      Aprix (CO);",
"     </li>",
"     <li>",
"      Aprix F (CO);",
"     </li>",
"     <li>",
"      Citodon (SE);",
"     </li>",
"     <li>",
"      Claradol Codeine (FR);",
"     </li>",
"     <li>",
"      Co-Codamol (HK);",
"     </li>",
"     <li>",
"      Cod-Acamol 10/500 (IL);",
"     </li>",
"     <li>",
"      Cod-Acamol 15/325 (IL);",
"     </li>",
"     <li>",
"      Codabrol (IL);",
"     </li>",
"     <li>",
"      Codalgin (AU, NZ);",
"     </li>",
"     <li>",
"      Codapane (AU);",
"     </li>",
"     <li>",
"      Codapane Forte (AU);",
"     </li>",
"     <li>",
"      Codeipar (CN);",
"     </li>",
"     <li>",
"      Codicet (TH);",
"     </li>",
"     <li>",
"      Codilprane Enfant (FR);",
"     </li>",
"     <li>",
"      Codipar (GB, IE);",
"     </li>",
"     <li>",
"      Coditam (ID);",
"     </li>",
"     <li>",
"      Codoliprane (FR);",
"     </li>",
"     <li>",
"      Codoliprane Enfant (FR);",
"     </li>",
"     <li>",
"      Dafalgan Codeine (FR);",
"     </li>",
"     <li>",
"      Dolaforte (AU);",
"     </li>",
"     <li>",
"      Dolorol Forte (ZA);",
"     </li>",
"     <li>",
"      Efferalgan Codeine (PY);",
"     </li>",
"     <li>",
"      Lusadeina Fuerte (PE);",
"     </li>",
"     <li>",
"      Maspara w/Codeine (TH);",
"     </li>",
"     <li>",
"      Maxadol (ZA);",
"     </li>",
"     <li>",
"      Nasa w/codeine (TH);",
"     </li>",
"     <li>",
"      Paceco (MY, SG);",
"     </li>",
"     <li>",
"      Panadeine (BB, BM, BS, BZ, CZ, GY, HK, HN, JM, MY, NL, NZ, PR, SR, TT);",
"     </li>",
"     <li>",
"      Panadeine Co (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Panadeine Forte (AU);",
"     </li>",
"     <li>",
"      Panadiene (AU, BB, BS, HK, JM, JP, MY, NL, NZ);",
"     </li>",
"     <li>",
"      Panado-Co Caplets (ZA);",
"     </li>",
"     <li>",
"      Panadol Duo (FI);",
"     </li>",
"     <li>",
"      Paracodol (ZA);",
"     </li>",
"     <li>",
"      Paradine (MY);",
"     </li>",
"     <li>",
"      Paramax (EE);",
"     </li>",
"     <li>",
"      Parcono (TH);",
"     </li>",
"     <li>",
"      Parcoten (HK);",
"     </li>",
"     <li>",
"      Perdolan codeine (BE);",
"     </li>",
"     <li>",
"      Prodeine Forte (AU);",
"     </li>",
"     <li>",
"      Prodeine-15 (AU);",
"     </li>",
"     <li>",
"      Rokamol Plus (IL);",
"     </li>",
"     <li>",
"      Solpadeine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Solpadol (GB, IE);",
"     </li>",
"     <li>",
"      TWC 30 (IN);",
"     </li>",
"     <li>",
"      Tylex CD (CR, DO, GT, MX, NI, PA, SV);",
"     </li>",
"     <li>",
"      Uphamol Plus Codeine (MY);",
"     </li>",
"     <li>",
"      Winadeine (EC);",
"     </li>",
"     <li>",
"      Winadeine F (EC);",
"     </li>",
"     <li>",
"      Winadol Forte (CO);",
"     </li>",
"     <li>",
"      Zapain (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F129466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits the synthesis of prostaglandins in the central nervous system and peripherally blocks pain impulse generation; produces antipyresis from inhibition of hypothalamic heat-regulating center; binds to opiate receptors in the CNS, causing inhibition of ascending pain pathways, altering the perception of and response to pain; causes cough supression by direct central action in the medulla; produces generalized CNS depression. Caffeine (contained in some non-U.S. formulations) is a CNS stimulant; use with acetaminophen and codeine increases the level of analgesia provided by each agent.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F129483\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Antlitz AM, Mead JA Jr, and Tolentino MA, &ldquo;Potentiation of Oral Anticoagulant Therapy by Acetaminophen,&rdquo;",
"      <i>",
"       Curr Ther Res Clin Exp",
"      </i>",
"      , 1968, 10(10):501-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/4971464/pubmed\" id=\"4971464\" target=\"_blank\">",
"        4971464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bagheri H, Bernhard NB, and Montastruc JL, &ldquo;Potentiation of the Acenocoumarol Anticoagulant Effect by Acetaminophen,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1999, 33(4):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/10332548/pubmed\" id=\"10332548\" target=\"_blank\">",
"        10332548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartle WR and Blakely JA, &ldquo;Potentiation of Warfarin Anticoagulation by Acetaminophen,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(10):1260.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/1995971/pubmed\" id=\"1995971\" target=\"_blank\">",
"        1995971",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeijinga JJ, Boerstra EE, Ris P, et al, &ldquo;Interaction Between Paracetamol and Coumarin Anticoagulants,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1982, 1(8270):506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/6121161/pubmed\" id=\"6121161\" target=\"_blank\">",
"        6121161",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, &ldquo;New Approaches to Preventing and Treating Postoperative Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):26-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/1619142/pubmed\" id=\"1619142\" target=\"_blank\">",
"        1619142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dionne RA, Campbell RA, Cooper SA, et al, &ldquo;Suppression of Postoperative Pain by Preoperative Administration of Ibuprofen in Comparison to Placebo, Acetaminophen, and Acetaminophen Plus Codeine,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1983, 23(1):37-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/6341415/pubmed\" id=\"6341415\" target=\"_blank\">",
"        6341415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Forbes JA, Butterworth GA, Burchfield WH, et al, &ldquo;Evaluation of Ketorolac, Aspirin, and an Acetaminophen-Codeine Combination in Postoperative Oral Surgery Pain,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1990, 10(6 Pt 2):77S-93S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/2082317/pubmed\" id=\"2082317\" target=\"_blank\">",
"        2082317",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gadisseur AP, Van Der Meer FJ, and Rosendaal FR, &ldquo;Sustained Intake of Paracetamol (Acetaminophen) During Oral Anticoagulant Therapy With Coumarins Does Not Cause Clinically Important INR Changes: A Randomized Double-Blind Clinical Trial,&rdquo;",
"      <i>",
"       J Thromb Haemost",
"      </i>",
"      , 2003, 1(4):714-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/12871405/pubmed\" id=\"12871405\" target=\"_blank\">",
"        12871405",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gebauer MG, Nyfort-Hansen K, Henschke PJ, et al, &ldquo;Warfarin and Acetaminophen Interaction,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2003, 23(1):109-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/12523469/pubmed\" id=\"12523469\" target=\"_blank\">",
"        12523469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gobetti JP, &ldquo;Controlling Dental Pain,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 1992, 123(6):47-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/1619145/pubmed\" id=\"1619145\" target=\"_blank\">",
"        1619145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hylek EM, Heiman H, Skates SJ, et al, &ldquo;Acetaminophen and Other Risk Factors for Excessive Warfarin Anticoagulation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(9):657-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/9496982/pubmed\" id=\"9496982\" target=\"_blank\">",
"        9496982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kwan D, Bartle WR, and Walker SE, \"The Effects of Acute and Chronic Acetaminophen Dosing on the Pharmacodynamics and Pharmacokinetics of (R)- and (S)-Warfarin,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1995, 57:212.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rubin RN, Mentzer RL, and Budzynski AZ, &ldquo;Potentiation of Anticoagulant Effect of Warfarin by Acetaminophen (Tylenol&reg;),&rdquo;",
"      <i>",
"       Clin Res",
"      </i>",
"      , 1984, 32:698a.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Bemt PM, Geven LM, Kuitert NA, et al, &ldquo;The Potential Interaction Between Oral Anticoagulants and Acetaminophen in Everyday Practice,&rdquo;",
"      <i>",
"       Pharm World Sci",
"      </i>",
"      , 2002, 24(5):201-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/5/10328/abstract-text/12426965/pubmed\" id=\"12426965\" target=\"_blank\">",
"        12426965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9251 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-197.136.42.3-E002DE631A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10328=[""].join("\n");
var outline_f10_5_10328=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14854545\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13114313\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129491\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129492\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129510\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129493\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129503\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129494\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129495\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129496\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129479\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8119602\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129463\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129512\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9378368\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129481\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129518\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129508\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129484\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129467\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129504\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129472\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129489\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129473\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5182920\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129498\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5182922\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129486\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2524294\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129476\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129487\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129466\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F129483\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9251\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9251|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?23/28/24005?source=related_link\">",
"      Acetaminophen and codeine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/12/5319?source=related_link\">",
"      Acetaminophen and codeine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_5_10329="Treatment of drug-resistant hypercholesterolemia";
var content_f10_5_10329=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of drug-resistant hypercholesterolemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Sarah D de Ferranti, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Paul Durrington, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10329/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/5/10329/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercholesterolemia, and in particular, an elevated level of serum (or plasma) low density lipoprotein cholesterol (LDL-C), is associated with an increased risk of adverse cardiovascular events. Lipid lowering drug therapy, particularly with statins, is indicated to decrease the risk of cardiovascular events in most individuals with established atherosclerotic cardiovascular disease and in many who are at high risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Statins are the preferred therapy for most patients requiring treatment of dyslipidemia and in particular those with an elevated LDL-C. The goals of therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=see_link\">",
"     \"Intensity of lipid lowering therapy in secondary prevention of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If after treatment with the maximal tolerated dose of statin the patient has not achieved the LDL-C goal, a number of other agents are available with varying levels of evidence for clinical benefits. These agents include nicotinic acid (niacin), bile acid sequestrants, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"     ezetimibe",
"    </a>",
"    and their use is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, some patients, including young individuals with severe hypercholesterolemia such as occurs in familial hypercholesterolemia, are unable to lower their LDL-C to values that approach prespecified targets with the use of these drugs. These individuals remain at high risk for cardiovascular events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=see_link\">",
"     \"Management of pediatric dyslipidemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss therapeutic options for these individuals which include low density lipoprotein (LDL) apheresis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"     lomitapide",
"    </a>",
"    , as well as a number of procedures which are rarely performed such as partial ileal bypass surgery, liver transplantation, and portocaval shunting. Gene therapy is a possible future alternative in selected patients such as those with FH, all of who have a defect in the LDL receptor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H4#H4\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Familial hypercholesterolemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557843\">",
"    <span class=\"h1\">",
"     DEFINITION OF DRUG-RESISTANT HYPERCHOLESTEROLEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who have undertaken lifestyle modification and who are on optimal doses of statin (and perhaps other lipid lowering agents) are unable to reach LDL-C goal. For the purpose of this topic, a patient is identified as having drug-resistant hypercholesterolemia if they are on optimal lipid lowering drug therapy and LDL-C remains &gt;250",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.17",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    without cardiovascular disease (CVD), or &gt;200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.10",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in the presence of established cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=see_link&amp;anchor=H2#H2\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\", section on 'Lifestyle modification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This definition is arbitrary but takes into account approved indications for LDL apheresis in Europe and the United States. It would not necessarily apply if (or when) other drugs that lower LDL-C become approved; it applies only to the use of technologies such as LDL apheresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1557919\">",
"    <span class=\"h1\">",
"     REFERRAL TO A SPECIALIST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have drug resistant hypercholesterolemia are not uncommon. We recommend that they be referred to a physician who has substantial expertise in managing such individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LDL APHERESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients at very high risk for serious cardiovascular events cannot reach their LDL-C goals with standard lipid lowering therapy. Low density lipoprotein (LDL) apheresis, which is approved by the United States Food and Drug Administration, has been recommended by some experts for these individuals. Patients who might be potential candidates include: those with coronary artery disease (CAD) and LDL-cholesterol levels greater than 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    after standard therapy; and those without established CAD, but at high risk due to an LDL-cholesterol level greater than 300",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    after dietary and pharmacologic intervention, who also have a first-degree relative with premature CAD, and the presence of additional risk factors such as low HDL-cholesterol or elevated lipoprotein (a) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/1\">",
"     1",
"    </a>",
"    ]. This group includes individuals with homozygous FH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=see_link\">",
"     \"Lipoprotein(a) and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325436636\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low density lipoprotein (LDL) apheresis refers to the extracorporeal removal of circulating apo B-containing lipoproteins, including LDL, lipoprotein (a), and very low density lipoprotein (VLDL). There are multiple apheresis methods, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    sulphate cellulose adsorption, heparin-induced extracorporeal LDL cholesterol precipitation, immunoadsorption, and double filtration plasma pheresis of lipoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/2\">",
"     2",
"    </a>",
"    ]. The procedure is performed weekly or biweekly, determined in part by the rate at which LDL levels return to baseline after therapy. It is available at a limited number of centers and cost is in the range of three to four thousand United States dollars per session.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325436643\">",
"    <span class=\"h2\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL apheresis lowers LDL-C acutely by 50 to 76 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. However, as the time averaged exposure to LDL-C is more likely a better measure of efficacy than the single post-treatment value, this number is often calculated (using multiple between treatment values) and has been found to be about 30 percent after six months and 38 percent after 18 months in the absence of statin therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients with higher baseline lipid levels appear to have a relatively greater response to this therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/6\">",
"     6",
"    </a>",
"    ]. The range of time for return to baseline level of LDL-C is four days to three to four weeks.",
"   </p>",
"   <p>",
"    The most frequent side effects include hypotension, anemia, nausea, flushing, and headache. Venous access is necessary and many patients require construction of an arteriovenous fistula which increases the long-term complications [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=see_link\">",
"     \"Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325436658\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;No study has demonstrated significantly improved survival with LDL apheresis. Some studies, which are limited by multiple potential sources of bias, the use of suboptimal doses of statins, or the enrollment of small numbers of patients, have suggested evidence of benefit for outcomes such as myocardial infarction. For example, in an observational study of 130 patients with heterozygous familial hypercholesterolemia (FH) who were treated with either LDL apheresis plus statin therapy (n = 43) or statin therapy (n = 87), there was a significantly lower rate of total coronary events (nonfatal myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, and death from coronary heart disease) in the LDL apheresis group (10 versus 36 percent, respectively) at six years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At least eight studies that evaluated angiographic parameters have evaluated the ability of LDL apheresis to reverse or delay the progression of atherosclerosis. Most of the patients in these studies had heterozygous FH; a few were homozygotes. Six of these studies were observational and in the aggregate did not show convincing evidence of regression [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/8\">",
"     8",
"    </a>",
"    ]. The two trials which randomly assigned patients to either LDL apheresis plus drug therapy or to drug therapy (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    or simvastatin plus a bile acid sequestrant) alone did not show any significant difference in angiographic outcome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Familial Hypercholesterolemia Regression Study randomly assigned 39 patients with heterozygous FH and coronary disease to biweekly LDL-apheresis plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to the same dose of simvastatin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"       colestipol",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/9\">",
"       9",
"      </a>",
"      ]. Repeat coronary angiography at approximately two years showed",
"      <strong>",
"       no difference",
"      </strong>",
"      in the mean change in luminal diameter but some secondary angiographic endpoints were biased in favor of drug therapy.",
"     </li>",
"     <li>",
"      The LDL-Apheresis Atherosclerosis Regression Study (LAARS) randomly assigned 42 patients with severe primary hypercholesterolemia (31 patients with heterozygous FH) and coronary atherosclerosis to biweekly LDL-apheresis plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      (40",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or to simvastatin alone [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/10\">",
"       10",
"      </a>",
"      ]. At two years, the mean reduction in LDL cholesterol was 63 and 47 percent, respectively. There was no difference in the degree of coronary atherosclerosis between the two groups. Repeat angiography revealed no difference within or between the two groups in the degree of coronary atherosclerosis, although more minor lesions disappeared in the apheresis group. LAARS also noted an improvement in regional myocardial perfusion in patients treated with apheresis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/11\">",
"       11",
"      </a>",
"      ] while another report showed improved endothelial function after a single apheresis [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The literature contains many case reports of children with homozygous FH undergoing LDL apheresis, many of whom had regression of xanthomata [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/8\">",
"     8",
"    </a>",
"    ]. The safety and efficacy of long-term LDL-apheresis was evaluated in a study of 11 children with severe genetic hypercholesterolemia (including children with homozygous FH) who were treated for 2 to 17 years [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/13\">",
"     13",
"    </a>",
"    ]. There were no cardiac deaths, non-fatal myocardial infarctions, or coronary revascularization procedures. Regression of established coronary artery lesions, as well as prevention of the development of new aortic and coronary lesions, was demonstrated.",
"   </p>",
"   <p>",
"    Studies have demonstrated improvement in the following cardiovascular effects of LDL apheresis: endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/12\">",
"     12",
"    </a>",
"    ], coronary vasodilation [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/14\">",
"     14",
"    </a>",
"    ], microvascular flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/15\">",
"     15",
"    </a>",
"    ], and myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/6,16\">",
"     6,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H174029240\">",
"    <span class=\"h2\">",
"     Clinical use",
"    </span>",
"    &nbsp;&mdash;&nbsp;LDL apheresis is an effective method of lowering LDL-cholesterol. However, in addition to the side effects and potential problems with access, cost and patient inconvenience severely limit its use. Initiation of this modality should be considered for patients with homozygous or heterozygous FH whose LDL-cholesterol levels are higher than those in the definition stated above after treatment with dietary and pharmacologic interventions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5093064\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2011 European Society of",
"    <span class=\"nowrap\">",
"     Cardiology/European",
"    </span>",
"    Atherosclerosis Society Guideline for the management of dyslipidaemias does not specifically recommend LDL apheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Third Report of the National (United States) Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report did not discuss LDL apheresis, in part because they were not intended to address patients with severe hypercholesterolemia associated with defined genetic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents makes the following statement: &ldquo;Children with homozygous familial hypercholesterolemia (FH) and extremely elevated LDL-cholesterol levels (500",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    have undergone effective LDL lowering therapy with biweekly LDL apheresis under the care of lipid specialists in academic medical centers&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The National Lipid Associated Expert Panel on FH list the following as possible indications for LDL apheresis in patients who, after six months, do not have an adequate response to maximum tolerated drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/6,20\">",
"     6,20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Functional homozygous FH patients with LDL-C &ge;300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (or non-HDL cholesterol 330",
"      <span class=\"nowrap\">",
"       mg/dL).",
"      </span>",
"     </li>",
"     <li>",
"      Functional heterozygous FH patients with LDL-C &ge;300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (or non-HDL cholesterol 330",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      and 0-1 risk factors).",
"     </li>",
"     <li>",
"      Functional heterozygous FH patients with LDL-C &ge;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (or non-HDL cholesterol 230",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and high risk characteristics such as &ge;2 risk factors or high lipoprotein (a) &ge;50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      using an isoform insensitive assay.",
"     </li>",
"     <li>",
"      Functional heterozygous FH patients with LDL-C &ge;160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (or non-HDL cholesterol 190",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      and very high risk characteristics such as established coronary heart disease, other cardiovascular disease, or diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PARTIAL ILEAL BYPASS SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of partial ileal bypass surgery was best assessed in the POSCH trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. The study population consisted of 838 patients, with an average age of 51 years, who had survived a first myocardial infarction. The mean follow-up period was 9.7 years. The following benefits were noted in those treated with surgery compared to the controls [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/21\">",
"     21",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A 23 percent reduction in the serum total cholesterol concentration (181 versus 236",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.71 versus 6.14",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"     </li>",
"     <li>",
"      A 38 percent reduction in serum LDL-cholesterol",
"     </li>",
"     <li>",
"      A nonsignificant reduction in overall mortality and mortality due to coronary heart disease",
"     </li>",
"     <li>",
"      A significant 35 percent reduction in the combined end point of death due to coronary heart disease and confirmed nonfatal myocardial infarction",
"     </li>",
"     <li>",
"      A comparison of base-line coronary arteriograms with those obtained at 3, 5, 7, and 10 years consistently showed less disease progression in the surgery group",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits persisted for five years after the trial (total mean follow-up 14.7 years) with significant reductions in cardiovascular and overall mortality, confirmed nonfatal myocardial infarction, incidence of coronary artery revascularization and onset of clinical peripheral vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common side effect of partial ileal bypass was diarrhea. Other problems included occasional kidney stones, gallstones, and intestinal obstruction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend partial ileal bypass surgery for patients with drug-resistant hypercholesterolemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     LIVER TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver transplantation is a procedure that has been used in familial hypercholesterolemia (FH) homozygous patients to provide the functional hepatic LDL receptors that these patients lack. Multiple case reports of children as young as five years of age have demonstrated that successful transplantation leads to normalization of LDL-C levels beginning as early as five days after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/24-27\">",
"     24-27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that liver transplantation is a reasonable treatment option for patients with homozygous familial hypercholesterolemia who do not approach LDL-C levels after treatment with maximal tolerated cholesterol lowering therapy and for whom receiving regular LDL-apheresis is not possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PORTOCAVAL SHUNT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Portocaval shunting has been evaluated in a limited number of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. One case report described a six-year-old girl with homozygous FH [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/28\">",
"     28",
"    </a>",
"    ]. Before surgery, the rate of synthesis of LDL was fourfold higher than in normolipidemic subjects and the fractional catabolic rate for LDL was reduced to 33 percent of control values. Five months after shunt surgery, the rate of LDL synthesis had declined by 48 percent. This caused a 39 percent reduction in the plasma LDL-cholesterol concentration despite a modest decrease in LDL catabolism. The mechanism of benefit was not well understood. Potential complications include hepatic encephalopathy and pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not recommend portocaval shunting for patients with drug-resistant hypercholesterolemia, except perhaps for those who cannot be transplanted or treated with LDL apheresis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4096656\">",
"    <span class=\"h1\">",
"     LOMITAPIDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In December of 2012, the United States Food and Drug Administration (FDA) approved the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"     lomitapide",
"    </a>",
"    for patients with",
"    <strong>",
"     homozygous",
"    </strong>",
"    familial hypercholesterolemia (FH), a rare inherited disorder that is estimated to occur in about one in a million individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H1056577219#H1056577219\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Homozygotes versus heterozygotes'",
"    </a>",
"    .) The package insert for lomitapide carries a Boxed Warning regarding a serious risk of liver toxicity, as its use is associated with liver enzyme abnormalities.",
"   </p>",
"   <p>",
"    For patients with homozygous FH, we suggest adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"     lomitapide",
"    </a>",
"    to treatment with a low fat diet, lipid-lowering drugs including statins and treatment with LDL apheresis or liver transplantation. For these patients who are not candidates for or refuse LDL-apheresis or liver transplantation, lomitapide should be considered as additional pharmacological therapy. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'LDL apheresis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"     Lomitapide",
"    </a>",
"    is a microsomal triglyceride transfer protein, which transfers triglycerides onto apolipoprotein B as part of the assembly of very low density lipoprotein within the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H11#H11\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Endogenous pathway of lipid metabolism'",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    The efficacy and safety of microsomal triglyceride transfer protein inhibition with the oral drug lomitapide has been evaluated in three small clinical studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of six patients with homozygous familial hypercholesterolemia,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"       lomitapide",
"      </a>",
"      (at doses ranging between 0.03 and 1.0 mg per kilogram of body weight per day) decreased LDL-C by 51 percent and apolipoprotein B by 56 percent from baseline values [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent phase 2 study took into account the side effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"       lomitapide",
"      </a>",
"      noted above. In this trial, 84 patients with moderate hypercholesterolemia (21-294",
"      <span class=\"nowrap\">",
"       md/dL",
"      </span>",
"      [5.49-7.62",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      , escalating doses of lomitapide (5, 7.5, and 10 mg per day), or ezetimibe plus escalating doses of lomitapide [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/32\">",
"       32",
"      </a>",
"      ]. After 12 weeks, LDL-C was lowered by 20, 30 (on 10 mg lomitapide), and 46 percent in the three groups, respectively. Lomitapide also reduced HDL-C by 6 percent and apoprotein B by 24 percent.",
"     </li>",
"     <li>",
"      In an open-label, phase 3, non-randomized, dose-escalating study, 29 patients with homozygous familial hypercholesterolemia over the age of 18 were treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"       lomitapide",
"      </a>",
"      at a median dose of 40 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/33\">",
"       33",
"      </a>",
"      ]. Most patients received high-dose statin and 18 patients underwent regular apheresis. After 26 weeks of therapy, LDL-C was reduced by approximately 50 percent from baseline (from 336 to 166",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [8.7",
"      <span class=\"nowrap\">",
"       mmol/L",
"      </span>",
"      to 4.3",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all three studies, the most common adverse events were gastrointestinal symptoms, increased liver aminotransferase levels, and hepatic fat accumulation. These side effects were dose-dependent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1142223\">",
"    <span class=\"h1\">",
"     POTENTIAL FUTURE APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are new drugs under development that could be used in advance of the procedural interventions described in this topic to achieve desirable LDL levels. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Mipomersen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"     Mipomersen",
"    </a>",
"    (ISIS 301012) is an antisense oligonucleotide complementary to the coding region for human apolipoprotein B (apo B) mRNA. Through direct binding to apo B mRNA, mipomersen inhibits apo B production. Apo B is the major structural component of LDL particles, and its metabolic precursors VLDL and IDL. The drug is generally given as a once weekly subcutaneous injection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"     Mipomersen",
"    </a>",
"    &rsquo;s application for marketing approval was reviewed by both United States and European regulatory authorities in 2102. A United States Food and Drug (FDA) advisory committee recommended approval of the drug in October 2012, but the FDA has not yet reported out its final decision. The Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) recommended that mipomersen not be approved for use due to concerns regarding safety [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/34\">",
"     34",
"    </a>",
"    ]. In clinical trials, many patients stopped taking the drug due to side effects such as flu-like symptoms, injections site reactions, and liver toxicity.",
"   </p>",
"   <p>",
"    The following studies have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"     mipomersen",
"    </a>",
"    :",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial of 36 adults with dyslipidemia,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"       mipomersen",
"      </a>",
"      reduced apo B levels by 13 to 50 percent and LDL cholesterol (LDL-C) levels by 4 to 44 percent in a dose-dependent fashion; at the highest doses the reductions were statistically significant compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a dose-escalating study of 74 hyperlipidemic patients on statin therapy,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"       mipomersen",
"      </a>",
"      significantly lowered the LDL-C level between 21 and 52 percent compared to placebo at five weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"       mipomersen",
"      </a>",
"      was evaluated in a study of 51 patients with homozygous familial hypercholesterolemia (FH), 12 years of age or older (mean age 30 to 33 years), who were being treated with maximal dose statin therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/37\">",
"       37",
"      </a>",
"      ]. The patients were randomly assigned in a 2:1 manner to either mipomersen 200 mg subcutaneously weekly (or 160 mg for body weight &lt;50 kg) or placebo. The mean serum LDL-C prior to initiation of therapy 425",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (11.0",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      After 26 weeks of treatment, patients taking mipomersen had a significantly greater lowering of LDL-C (mean -24.7 versus -3.3 percent with the mean attained serum cholesterol being 330",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [8.6",
"      <span class=\"nowrap\">",
"       mmol/L]).",
"      </span>",
"     </li>",
"     <li>",
"      The efficacy and safety of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"       mipomersen",
"      </a>",
"      was evaluated in a study of 124 patients with heterozygous FH and coronary artery disease who were treated with maximally tolerated statin and had LDL-C &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/38\">",
"       38",
"      </a>",
"      ]. Patients were randomly assigned in a 2:1 manner to either weekly subcutaneous mipomersen 200 mg or placebo for 26 weeks. After 28 weeks, mipomersen decreased LDL-C (-28 percent [95% CI -34 to &ndash;22.1 percent]) compared to an increase with placebo (5.2 percent [95% CI -0.5 to 10.9 percent]). Compared to placebo, mipomersen significantly reduced apolipoprotein B as well as lipoprotein(a).",
"     </li>",
"     <li>",
"      In a study of 33 individuals who were statin intolerant and at high risk for cardiovascular disease, patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"       mipomersen",
"      </a>",
"      or placebo in a 2:1 manner [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/39\">",
"       39",
"      </a>",
"      ]. After 26 weeks, mipomersen lead to a 47 percent reduction in LDL-C.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In these studies, the most common adverse events have been injection site reactions, flu-like symptoms, and persistent increases in serum alanine aminotransferase levels &ge;3 times the upper limit of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Gene therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene therapy, supplying the normal LDL receptor gene for the treatment of FH, has been tested in mice and human subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H550824534\">",
"    <span class=\"h2\">",
"     Monoclonal antibody to PCSK9",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proprotein convertase subtilisin kexin 9 (PCKS9) is a serine protease that leads to the degradation of LDL receptors and increased LDL-C levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=see_link&amp;anchor=H780943178#H780943178\">",
"     \"Inherited disorders of LDL-cholesterol metabolism\", section on 'Mutations in the PCSK9 gene'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A human monoclonal antibody to PCSK9 lowered LDL-C levels by up to 64 percent (in a dose dependent manner) in multiple phase I trials of healthy volunteers or individuals with either familial or nonfamilial forms of hypercholesterolemia, including some subjects who were taking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. As patients with homozygous FH have no functional LDL-receptors, this therapy is not likely to be effective in these individuals.",
"   </p>",
"   <p>",
"    Multiple phase II trials of subcutaneously administered monoclonal antibody to PCSK9 (either as",
"    <span class=\"nowrap\">",
"     REGN727/SAR236553",
"    </span>",
"    or AMG 145) that have enrolled differing populations found that the antibody significantly lowers LDL-C, in a dose dependent manner, by as much as 70 percent. No severe or life-threatening adverse events have been attributed to the treatment. In addition, the drug appears to be relatively well tolerated, although the need to administer the drug subcutaneously may impact its ability to be used in some patients. Despite the promise of this therapy, phase III trials with several years of follow-up are needed to evaluate the impact on clinical outcomes and long-term safety. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 183 patients with primary hypercholesterolemia and LDL-C levels &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.59",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on stable-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (10, 20, or 40 mg), individuals were randomly assigned to differing doses of",
"      <span class=\"nowrap\">",
"       REGN727/SAR236553",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/45\">",
"       45",
"      </a>",
"      ]. A dose response (with regard to LDL-C as measured by the Friedewald formula) was found (the maximal reduction from baseline was 72 percent in the group taking 150 mg every two weeks) and the drug was effective at all atorvastatin doses.",
"     </li>",
"     <li>",
"      In a study of 92 patients with primary hypercholesterolemia and LDL-C levels &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.59",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on stable-dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      (10 mg), individuals were randomly assigned to eight weeks of treatment with atorvastatin 80 mg daily plus",
"      <span class=\"nowrap\">",
"       REGN727/SAR236553",
"      </span>",
"      once every two weeks, atorvastatin 10 mg daily plus",
"      <span class=\"nowrap\">",
"       REGN727/SAR236553",
"      </span>",
"      once every two weeks, or atorvastatin 80 mg daily plus placebo every two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/46\">",
"       46",
"      </a>",
"      ]. After eight weeks of treatment, the percent reduction from baseline in LDL-C (using the Friedewald formula) was 72, 66, and 17 percent, respectively.",
"     </li>",
"     <li>",
"      In a study of 77 individuals with heterozygous familial hypercholesterolemia and LDL-C concentrations of 100.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or higher on high dose, potent statin therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"       rosuvastatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"       simvastatin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"       atorvastatin",
"      </a>",
"      ), patients were randomly assigned to 150 mg, 200 mg, or 300 mg of",
"      <span class=\"nowrap\">",
"       REGN727/SAR236553",
"      </span>",
"      every four weeks, or 150 mg every two weeks, or placebo every two weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/47\">",
"       47",
"      </a>",
"      ]. At week 12, there was a significant mean percent reduction in LDL-C (using the Friedewald formula) from baseline of 28.9, 31.5, 42.5, and 67.9 for the four drug doses, respectively, compared to 10.6 percent with placebo.",
"     </li>",
"     <li>",
"      In the RUTHERFORD trial, 168 patients with heterozygous familial hypercholesterolemia and LDL-C levels &ge;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&ge;2.60",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      on statin therapy with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      were randomly assigned in a 1:1:1 manner to 350 or 420 mg of AMG 145 or placebo administered subcutaneously every four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/48\">",
"       48",
"      </a>",
"      ]. The mean baseline LDL-C was 158.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.1",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      After 12 weeks, LDL-C reduction (measured by ultracentrifugation) fell by 43 and 55 percent in the two drug groups respectively, compared with a 1 percent rise in the placebo group.",
"     </li>",
"     <li>",
"      In the GAUSS trial, 160 hypercholesterolemic patients (mean baseline LDL-C of 193",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [4.99",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      who were intolerant to optimal statin therapy because of muscle-related events were randomly assigned to AMG 14 alone at doses of 280 mg, 350 mg, or 420 mg or AMG 145 420 mg plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      10 mg, or ezetimibe 10 plus placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/49\">",
"       49",
"      </a>",
"      ]. The mean baseline LDL-C was 193",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.99",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      At week 12, mean LDL-C levels (measured by ultracentrifugation) fell by 41, 42, 51, 63 percent compared with 15 percent in the",
"      <span class=\"nowrap\">",
"       placebo/ezetimibe",
"      </span>",
"      group.",
"     </li>",
"     <li>",
"      In the LAPLACE-TIMI 57 study, 631 hypercholesterolemic patients treated with a stable dose of a statin (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      ) were randomly assigned to AMG 145 at 70, 105, or 140 mg or placebo every two weeks or AMG 145 at 280, 350, or 420 mg or placebo every four weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/50\">",
"       50",
"      </a>",
"      ]. The mean baseline LDL-C was 123.7",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.2",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      At week 12, mean LDL-C concentrations (measured by ultracentrifugation) were reduced by AMG 145 mg every two weeks from 42 to 66 percent versus placebo and AMG 145 every four weeks from 42 to 50 percent.",
"     </li>",
"     <li>",
"      In the MENDEL, 406 untreated hypercholesterolemic patients with LDL-C concentrations between 100.5 and 189.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (2.6 to 4.9",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      were randomly assigned to AMG 145 at 70, 105, or 140 mg or placebo every two weeks, AMG 145 at 280, 350, or 420 mg or placebo every four weeks, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/42/4773?source=see_link\">",
"       ezetimibe",
"      </a>",
"      10 mg daily [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/51\">",
"       51",
"      </a>",
"      ]. The mean baseline LDL-C was 143",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.7",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      At week 12, mean LDL-C concentrations (measured by ultracentrifugation) were reduced to a comparable extent as found the studies cited above (39 to 51 percent). Treatment with ezetimibe decreased LDL-C by about 15 percent and placebo led to an increase of about 4 percent in both placebo groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H549907274\">",
"    <span class=\"h2\">",
"     Antibody removal of resistin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistin is an adipose tissue-derived serum protein (adipokine) that is increased in obesity and is positively correlated with atherosclerotic cardiovascular disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathogenesis of type 2 diabetes mellitus\", section on 'Resistin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In-vitro studies of its function have demonstrated that resistin is able to down-regulate LDL-receptor expression, potentially by increasing the expression of PCSK9 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10329/abstract/52\">",
"     52",
"    </a>",
"    ]. These studies also showed that antibody-immunoprecipitation removal of resistin in human serum from obese individuals leads to an increase in LDL-receptors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H325436680\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients, including young individuals with severe hypercholesterolemia such as occurs in severe or compound heterozygous or homozygous familial hypercholesterolemia (FH), are unable to lower their low density lipoprotein-cholesterol (LDL-C) to values that approach prespecified targets with diet and established lipid lowering therapy, including statins. These individuals remain at high risk for cardiovascular events. Our recommendations for further treatment of these individuals are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with",
"      <strong>",
"       heterozygous",
"      </strong>",
"      FH who, after six months of dietary and optimal drug therapy, have an LDL-C above 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.17",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      and have no established cardiovascular disease, or above 160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the presence of established cardiovascular disease, we suggest LDL apheresis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'LDL apheresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with",
"      <strong>",
"       homozygous",
"      </strong>",
"      FH who do not achieve LDL-C &lt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.17",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the absence of cardiovascular disease or LDL-C &lt;160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in patients with established disease who are on maximal medical therapy, we suggest either LDL-apheresis or liver transplantation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The decision between the two should be based on issues of availability, patient preference, and expertise in performing liver transplantation (including operative mortality). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'LDL apheresis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Liver transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For",
"      <strong>",
"       homozygous",
"      </strong>",
"      FH patients without cardiovascular disease who do not achieve LDL-C &lt;200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (5.17",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      or those with established disease who do not achieve an LDL-C &lt;160",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (4.10",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      after optimal drug therapy and either LDL-apheresis or liver transplantation, we suggest adding",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/35/23095?source=see_link\">",
"       lomitapide",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients who are not candidates for or refuse LDL-apheresis or liver transplantation, lomitapide should be considered as additional pharmacologic therapy.",
"     </li>",
"     <li>",
"      Ileal bypass and portocaval shunt should not be used except in unusual circumstances. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other promising but investigational therapies, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16789?source=see_link\">",
"     mipomersen",
"    </a>",
"    and gene therapy are under investigation for homozygous FH patients, and monoclonal antibody to PCSK9 has shown efficacy in heterozygous FH individuals.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/1\">",
"      Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. Am J Cardiol 1994; 74:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/2\">",
"      Thompson GR, Catapano A, Saheb S, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol 2010; 21:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/3\">",
"      Thompson GR, HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 2008; 198:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/4\">",
"      Hemphill LC. Familial hypercholesterolemia: current treatment options and patient selection for low-density lipoprotein apheresis. J Clin Lipidol 2010; 4:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/5\">",
"      Pfohl M, Naoumova RP, Klass C, et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 1994; 35:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/6\">",
"      Ito MK, McGowan MP, Moriarty PM, National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/7\">",
"      Mabuchi H, Koizumi J, Shimizu M, et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998; 82:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/8\">",
"      Thompson GR. LDL apheresis. Atherosclerosis 2003; 167:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/9\">",
"      Thompson GR, Maher VM, Matthews S, et al. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995; 345:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/10\">",
"      Kroon AA, Aengevaeren WR, van der Werf T, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/11\">",
"      Aengevaeren WR, Kroon AA, Stalenhoef AF, et al. Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS). J Am Coll Cardiol 1996; 28:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/12\">",
"      Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/13\">",
"      Stefanutti C, Vivenzio A, Di Giacomo S, et al. Aorta and coronary angiographic follow-up of children with severe hypercholesterolemia treated with low-density lipoprotein apheresis. Transfusion 2009; 49:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/14\">",
"      Igarashi K, Tsuji M, Nishimura M, Horimoto M. Improvement of endothelium-dependent coronary vasodilation after a single LDL apheresis in patients with hypercholesterolemia. J Clin Apher 2004; 19:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/15\">",
"      Sato M, Amano I. Changes in oxidative stress and microcirculation by low-density lipoprotein apheresis. Ther Apher Dial 2003; 7:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/16\">",
"      Kobayashi K, Yamashita K, Tasaki H, et al. Evaluation of improved coronary flow velocity reserve using transthoracic Doppler echocardiography after single LDL apheresis. Ther Apher Dial 2004; 8:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/17\">",
"      European Association for Cardiovascular Prevention &amp; Rehabilitation, Reiner Z, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32:1769.",
"     </a>",
"    </li>",
"    <li>",
"     Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report National Cholesterol Education Program. NIH Publication No. 02-5215, National Heart, Lung, and Blood Institute, National Institutes of Health; 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/19\">",
"      Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/20\">",
"      Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: screening, diagnosis and management of pediatric and adult patients: clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/21\">",
"      Buchwald H, Varco RL, Matts JP, et al. Effect of partial ileal bypass surgery on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. Report of the Program on the Surgical Control of the Hyperlipidemias (POSCH). N Engl J Med 1990; 323:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/22\">",
"      Buchwald H, Matts JP, Fitch LL, et al. Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) Group. JAMA 1992; 268:1429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/23\">",
"      Buchwald H, Varco RL, Boen JR, et al. Effective lipid modification by partial ileal bypass reduced long-term coronary heart disease mortality and morbidity: five-year posttrial follow-up report from the POSCH. Program on the Surgical Control of the Hyperlipidemias. Arch Intern Med 1998; 158:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/24\">",
"      Bilheimer DW, Goldstein JL, Grundy SM, et al. Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia. N Engl J Med 1984; 311:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/25\">",
"      Valdivielso P, Escolar JL, Cuervas-Mons V, et al. Lipids and lipoprotein changes after heart and liver transplantation in a patient with homozygous familial hypercholesterolemia. Ann Intern Med 1988; 108:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/26\">",
"      Kakaei F, Nikeghbalian S, Kazemi K, et al. Liver transplantation for homozygous familial hypercholesterolemia: two case reports. Transplant Proc 2009; 41:2939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/27\">",
"      Maiorana A, Nobili V, Calandra S, et al. Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatr Transplant 2011; 15:E25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/28\">",
"      Bilheimer DW, Goldstein JL, Grundy SM, Brown MS. Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a patient with homozygous familial hypercholesterolemia. J Clin Invest 1975; 56:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/29\">",
"      Starzl TE, Putnam CW, Koep LJ. Portacaval shunt and hyperlipidemia. Arch Surg 1978; 113:71.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333285.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/31\">",
"      Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007; 356:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/32\">",
"      Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/33\">",
"      Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013; 381:40.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002429/smops/Negative/human_smop_000460.jsp&amp;mid=WC0b01ac058001d127&amp;source=homeMedSearch&amp;category=human.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/35\">",
"      Kastelein JJ, Wedel MK, Baker BF, et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006; 114:1729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/36\">",
"      Akdim F, Stroes ES, Sijbrands EJ, et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010; 55:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/37\">",
"      Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/38\">",
"      Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: Results of a randomized, double-blind, placebo controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/39\">",
"      Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012; 33:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/40\">",
"      Oka K, Pastore L, Kim IH, et al. Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor. Circulation 2001; 103:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/41\">",
"      Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995; 1:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/42\">",
"      Van Craeyveld E, Jacobs F, Gordts SC, De Geest B. Gene therapy for familial hypercholesterolemia. Curr Pharm Des 2011; 17:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/43\">",
"      Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/44\">",
"      Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol 2012; 60:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/45\">",
"      McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59:2344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/46\">",
"      Roth EM, McKenney JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012; 367:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/47\">",
"      Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet 2012; 380:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/48\">",
"      Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation 2012; 126:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/49\">",
"      Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA 2012; 308:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/50\">",
"      Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/51\">",
"      Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; 380:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10329/abstract/52\">",
"      Melone M, Wilsie L, Palyha O, et al. Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 2012; 59:1697.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4554 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-F6CCE2A0D3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10329=[""].join("\n");
var outline_f10_5_10329=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H325436680\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1557843\">",
"      DEFINITION OF DRUG-RESISTANT HYPERCHOLESTEROLEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1557919\">",
"      REFERRAL TO A SPECIALIST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LDL APHERESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H325436636\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H325436643\">",
"      Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H325436658\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H174029240\">",
"      Clinical use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5093064\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PARTIAL ILEAL BYPASS SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      LIVER TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PORTOCAVAL SHUNT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4096656\">",
"      LOMITAPIDE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1142223\">",
"      POTENTIAL FUTURE APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Mipomersen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Gene therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H550824534\">",
"      Monoclonal antibody to PCSK9",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H549907274\">",
"      Antibody removal of resistin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H325436680\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37274?source=related_link\">",
"      Inherited disorders of LDL-cholesterol metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/59/3002?source=related_link\">",
"      Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/19/40248?source=related_link\">",
"      Lipoprotein(a) and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12282?source=related_link\">",
"      Management of pediatric dyslipidemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/15/12536?source=related_link\">",
"      Non-thrombotic complications of chronic hemodialysis arteriovenous vascular access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_5_10330="Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety";
var content_f10_5_10330=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Vasodilator stress radionuclide myocardial perfusion imaging: Testing methodologies and safety",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Gary V Heller, MD, PhD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Justin B Lundbye, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Athanasios Kapetanopoulos, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Patricia A Pellikka, MD, FACC, FAHA, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/5/10330/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/5/10330/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stress radionuclide myocardial perfusion imaging (rMPI) is an established method for detecting coronary artery disease (CAD) and risk assessment. Although exercise stress testing is generally preferred since it provides functional and hemodynamic information, pharmacologic stress provides an alternative means of evaluation in patients who are not able to attain an adequate level of exercise. Vasodilator stress rMPI is the most common type of pharmacologic stress rMPI.",
"   </p>",
"   <p>",
"    The safety, contraindications and study protocol of various types of vasodilator stress rMPI will be reviewed here.",
"   </p>",
"   <p>",
"    The clinical use of vasodilator stress rMPI for the diagnosis of CAD, for risk stratification, and for use in specific settings as well as general discussions on the use of stress testing for the diagnosis and prognosis of known or suspected CAD, including its prognostic role after an acute coronary syndrome or revascularization, and the advantages and limitations of various types of stress tests are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=see_link\">",
"     \"Stress testing for the diagnosis of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=see_link\">",
"     \"Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=see_link\">",
"     \"Selecting the optimal cardiac stress test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TEST OPTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Choice of stress method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of stress method is largely governed by patient characteristics. For patients in whom radionuclide myocardial perfusion imaging is indicated, an algorithm for stress method selection is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef87155 \" href=\"UTD.htm?26/46/27363\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Symptom-limited treadmill or bicycle exercise is the preferred form of stress for patients who attain an adequate level of exercise (defined as &ge;85 percent of their predicted maximal heart rate) because it provides the most information concerning patient symptoms, cardiovascular function, and the hemodynamic response during usual forms of activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The inability to perform an exercise test is in itself a marker of increased risk in patients with coronary artery disease (CAD). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H10#H10\">",
"     \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Exercise capacity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=see_link\">",
"     \"Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are unable to attain an adequate level of exercise due to advanced age, peripheral vascular disease, arthritis, morbid obesity, or other comorbidities, vasodilator stress rMPI provides an important alternative to achieve coronary hyperemia. Inadequate exercise may lead to an underestimation of the presence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity of CAD and ischemia. Submaximal exercise may reduce the diagnostic accuracy of exercise rMPI, leading to potentially inappropriate risk stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Thus, at least 40 percent of patients referred for rMPI undergo pharmacologic stress. Importantly, they represent an overall higher risk group for future cardiac events compared to patients who can exercise, even in the presence of normal perfusion imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pharmacologic stress agents are classified as either vasodilator or",
"    <span class=\"nowrap\">",
"     inotropic/chronotropic",
"    </span>",
"    drugs (",
"    <a class=\"graphic graphic_table graphicRef71371 \" href=\"UTD.htm?3/42/3757\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major vasodilators used for pharmacologic rMPI are adenosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      . These drugs produce coronary vasodilation resulting in hyperemia; the detection of differences in coronary hyperemia between stenosed and normal vascular territories is the basis for production of perfusion defects by MPI. Unless contraindicated, they are the first choice for rMPI pharmacologic stress and they can be combined with low-level exercise (",
"      <a class=\"graphic graphic_algorithm graphicRef87155 \" href=\"UTD.htm?26/46/27363\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/1\">",
"       1",
"      </a>",
"      ]. Although adenosine triphosphate is used in Japan, this agent is not approved in the USA.",
"     </li>",
"     <li>",
"      The major",
"      <span class=\"nowrap\">",
"       inotropic/chronotropic",
"      </span>",
"      agent used for pharmacologic rMPI is",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      (with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      ). Dobutamine augments myocardial contractility, heart rate, and cardiac output, resulting in increased oxygen demand and secondary coronary vasodilation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    is recommended in the following patients (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=see_link\">",
"     \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have contraindications to vasodilators, including those with reactive airway disease (adenosine and, indirectly,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      may precipitate bronchospasm in such patients). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Contraindications to vasodilators'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients who are taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"       theophylline",
"      </a>",
"      or have ingested caffeine within the past 12 hours (both are adenosine receptor antagonists and can interfere with imaging results). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19946?source=see_link\">",
"       \"Impact of medications and methylxanthines on stress testing\"",
"      </a>",
"      .) Caffeine, taken as one cup of coffee one hour prior to the procedure, may not appear to interfere with adenosine SPECT perfusion imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    have similar sensitivity and specificity for the diagnosis of CAD. They all can be used during either single photon emission computed tomography (SPECT) or positron emission tomography (PET) imaging. There currently is no data available on sensitivity for PET imaging using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Choice of isotope",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, two 99m-technetium (Tc)-labeled perfusion agents are primarily used for SPECT clinical testing: 99m-Tc-sestamibi and 99m-Tc-tetrofosmin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=see_link\">",
"     \"Basic properties of myocardial perfusion agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=see_link\">",
"     \"Clinical syndromes of stunned or hibernating myocardium\"",
"    </a>",
"    .) Marked liver uptake is noted for both agents, particularly during pharmacologic stress, and is a limitation to interpretation. Although thallium -201 is available, it is seldom used for stress testing because of its lower energy and higher attenuation and scatter as compared to technetium labeled tracers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=see_link\">",
"     \"Basic properties of myocardial perfusion agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of cardiac PET perfusion imaging is increasing and data suggest superiority over SPECT imaging in the evaluation of patients with known or suspected CAD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Advantages of PET over SPECT imaging include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Higher spatial, temporal and contrast resolution",
"     </li>",
"     <li>",
"      Higher energy tracers with much shorter radiopharmaceutical half-life, resulting in enhanced overall image quality",
"     </li>",
"     <li>",
"      Quantitative assessment of myocardial blood flow",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data indicate that PET has higher diagnostic accuracy compared to SPECT imaging and it is particularly useful in imaging of patients with obesity, equivocal SPECT results, and for the detection of multivessel CAD [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Based on the 2003 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/10\">",
"     10",
"    </a>",
"    ], vasodilator PET perfusion imaging is indicated in patients with equivocal SPECT results or as an alternative initial test in patients who cannot exercise.",
"   </p>",
"   <p>",
"    The currently FDA approved and clinically used PET perfusion agents include Rubidium-82 and 13N-ammonia. 13N-Ammonia use is restricted to centers with an available on-site cyclotron. Rubidium-82 is produced from a strontium-82 generator and it is widely used in centers without on-site cyclotrons. Vasodilator stress is usually preferred because exercise, although feasible, poses technical challenges during PET perfusion imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    is an alternative when vasodilators are contraindicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     MECHANISM OF VASODILATOR STRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are effective pharmacologic stress agents because they produce coronary vasodilation, increasing myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. The magnitude of this effect was illustrated in a study using positron emission tomography (PET) in normal men; myocardial blood flow increased from 1.1",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per gram at rest to 4.4 and 4.3",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per gram after adenosine and dipyridamole, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/12\">",
"     12",
"    </a>",
"    ]. However, there was substantial interpatient variability in response (eg, from 2.0 to 8.4",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per gram with adenosine).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Relative flow differences",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of significant obstructive coronary artery disease leads to perfusion defects during vasodilator stress rMPI. These defects reflect the heterogeneity in coronary flow reserve between normal and stenosed coronary artery territories [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/13,15-17\">",
"     13,15-17",
"    </a>",
"    ]. Blood flow in normal coronary arteries may increase up to fourfold in response to increased demand. Endogenously-produced adenosine causes direct relaxation of the coronary arterioles (resistance vessels), which results in increased blood flow. In the presence of coronary stenosis, part of the coronary flow reserve has been used in order to maintain resting blood flow. Consequently, in a moderately-narrowed artery the blunted coronary flow reserve can be detected if a perfusion tracer is injected during adenosine-induced hyperemia. The tracer uptake in the myocardium supplied by the narrowed artery will be reduced compared to the myocardium supplied by arteries without significant stenosis. Coronary flow reserve is exhausted in severely-stenosed arteries and even resting blood flow could be diminished. Both SPECT and PET imaging can detect these regional differences of tracer uptake. Absolute quantification of coronary blood flow is currently possible only with PET imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coronary steal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary steal during vasodilation refers to an absolute decrease in flow distal to a coronary stenosis in response to coronary vasodilation occurring either within the coronary artery territory (endocardial to epicardial) or between coronary artery territories [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/18-20\">",
"     18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intracoronary steal (from endocardium to subepicardial territory) occurs because of higher vasodilator reserve in the subepicardial vessels compared to subendocardial vessels.",
"     </li>",
"     <li>",
"      Intercoronary steal occurs when the coronary bed distal to a severe stenosis is perfused with collaterals from another coronary artery territory. During vasodilatation, resistance in the normal coronary artery falls, resulting in increased flow in areas without stenosis and reduced collateral flow to the region supplied by the stenotic artery segment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=see_link\">",
"       \"Coronary collateral circulation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A perfusion defect",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ST segment depression or elevation can occur if coronary steal produces significant myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In a report of 18 patients with multivessel coronary artery disease who underwent PET imaging with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , for example, coronary steal occurred in eight [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/20\">",
"     20",
"    </a>",
"    ]. In the patients with steal, myocardial blood flow fell from 90 to 68",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per min after dipyridamole in the segments with steal, and increased from 87 to 138",
"    <span class=\"nowrap\">",
"     mL/100",
"    </span>",
"    g per min in the segments without steal. Steal was associated with either ST elevation or the combination of ST depression and angina.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     ST segment depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of ST segment depression is less common with vasodilator stress compared to treadmill exercise testing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/19,21-23\">",
"     19,21-23",
"    </a>",
"    ]. ST segment depression occurring during pharmacologic stress has a high positive predictive value (90 percent); however, 70 percent of patients with CHD show no ECG changes but positive imaging results.",
"   </p>",
"   <p>",
"    A study of 65 patients with CHD and reversible thallium defects on adenosine infusion assessed which patients might develop ST segment depression during vasodilator stress [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/19\">",
"     19",
"    </a>",
"    ]. Independent predictors of ST segment depression, which occurred in one-third of patients, included the presence of collaterals at angiography (which may predispose to coronary steal), higher baseline systolic blood pressure, and the development of typical angina during infusion. In comparison, the size of the perfusion defects and the extent of CHD were not predictors of ST segment depression.",
"   </p>",
"   <p>",
"    Thus, a positive ECG response to vasodilator stress is a marker of significant coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/19\">",
"     19",
"    </a>",
"    ] and may warrant further evaluation even in the presence of normal rMPI [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/24\">",
"     24",
"    </a>",
"    ]. In comparison, the development of nonspecific chest pain during adenosine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    stress is not clearly associated with CHD and can occur in healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/25\">",
"     25",
"    </a>",
"    ]. ECG changes suggestive of ischemia were observed equally with adenosine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Left ventricular dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient left ventricular dilation, or dilatation of the left ventricle at peak stress compared to rest, can occur (37 percent of cases in one series) during pharmacologic stress testing (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80109 \" href=\"UTD.htm?0/61/980\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/27\">",
"     27",
"    </a>",
"    ]. It likely represents an absolute or relative decrease in subendocardial blood flow, has a strong association with electrocardiographic signs of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/27\">",
"     27",
"    </a>",
"    ], correlates with the severity and extent of the perfusion abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/28\">",
"     28",
"    </a>",
"    ], is a marker of high risk, and is a strong independent predictor of cardiac events&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     VASODILATOR AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available vasodilator stress agents work by stimulation of the adenosine A2A receptors. The 2009 update of the American Society of Nuclear Cardiology guidelines for nuclear cardiology procedures includes protocols for use of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adenosine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine is a purine nucleoside molecule that has several important cardioprotective properties, including regulation of coronary blood flow and heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/33\">",
"     33",
"    </a>",
"    ]. Endogenous adenosine is produced via the metabolism of ATP and through the S-adenosyl methionine (SAM) pathway in the cytoplasm of most cells. It then crosses the cell membrane to interact with specific receptors (",
"    <a class=\"graphic graphic_figure graphicRef58329 \" href=\"UTD.htm?34/26/35247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activation of adenosine A2A receptors causes coronary vasodilatation through the production of cyclic AMP, stimulation of potassium channels, and decreased intracellular calcium uptake.",
"     </li>",
"     <li>",
"      Activation of A1 receptors causes atrioventricular (AV) conduction delay, explaining its use in the management of supraventricular arrhythmia.",
"     </li>",
"     <li>",
"      Activation of A2B, A3, A4 receptors can mediate bronchospasm by facilitating mast cell degranulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cardiovascular effects of adenosine include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Potent vasodilatation",
"     </li>",
"     <li>",
"      Increase in heart rate, due to vagal inhibition at low doses",
"     </li>",
"     <li>",
"      Potential for bradycardia and AV block at high doses",
"     </li>",
"     <li>",
"      Reduced adrenergic activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After activation of the adenosine receptors, adenosine reenters the cell and is converted to ATP and SAM or deaminated to inosine (",
"    <a class=\"graphic graphic_figure graphicRef58329 \" href=\"UTD.htm?34/26/35247\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/34\">",
"     34",
"    </a>",
"    ]. Exogenously administered adenosine is rapidly taken up by the cells, especially red blood cells and endothelial cells, explaining the remarkably short half-life of five seconds.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Study protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine is administered via an infusion pump at a dose of 140",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min for six minutes. The radionuclide is given after three minutes of adenosine infusion and the infusion is continued for a further three minutes (",
"    <a class=\"graphic graphic_figure graphicRef60268 \" href=\"UTD.htm?30/2/30766\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/31,32\">",
"     31,32",
"    </a>",
"    ], although some investigators have suggested discontinuation of the infusion two minutes after the radionuclide injection. Simultaneous low level treadmill stress during adenosine infusion is safe, feasible, well tolerated, results in fewer side effects, and improves image quality [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other less validated protocols are also utilized. These include a shorter four minute protocol. Adenosine is administered via a pump at a dose of 140",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min and the radioisotope is injected at the three minute mark of a four minute protocol [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Dipyridamole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    produces vasodilation by blocking the cellular reuptake of adenosine, thereby elevating the interstitial concentration of endogenous adenosine and increasing adenosine activity [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. The biologic half-life of dipyridamole is 30 to 45 minutes; it is primarily metabolized in the liver and only small amounts are excreted in urine (",
"    <a class=\"graphic graphic_table graphicRef71371 \" href=\"UTD.htm?3/42/3757\">",
"     table 1",
"    </a>",
"    ). As a result, dipyridamole should be used cautiously in patients with hepatic dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Study protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    is the most widely utilized pharmacologic stress for radionuclide myocardial perfusion imaging. Dipyridamole is infused at a dose of 140",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min for four minutes, up to a maximum dose of 0.56",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    the radionuclide is injected seven to nine minutes after initiation of the infusion or three to five minutes after the completion of dipyridamole [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. To reverse side effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    125 to 250 mg intravenously is often required and is usually given one to two minutes following radionuclide injection.",
"   </p>",
"   <p>",
"    Because of the longer half-life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    compared to adenosine, patients can receive a dipyridamole infusion and then undergo any level of supplemental exercise. When combined with treadmill exercise testing, the injection of radionuclide is given at one minute prior to peak exercise (",
"    <a class=\"graphic graphic_figure graphicRef74036 \" href=\"UTD.htm?23/63/24573\">",
"     figure 3",
"    </a>",
"    ). A longer duration of exercise helps improve the image quality by reducing liver activity, and provides additional clinical information, including exercise capacity, onset of symptoms, and ECG changes. Furthermore, functional data from symptom-limited exercise testing after dipyridamole infusion enhance risk stratification for future cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=see_link&amp;anchor=H10#H10\">",
"     \"Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease\", section on 'Vasodilator stress combined with exercise ECG testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of protocols have been described for vasodilator PET perfusion imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/39\">",
"     39",
"    </a>",
"    ]. UpToDate prefers a 30 minute protocol for Rubidium-82 gated PET perfusion imaging, generally with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    as the stress agent (",
"    <a class=\"graphic graphic_figure graphicRef80718 \" href=\"UTD.htm?37/0/37901\">",
"     figure 4",
"    </a>",
"    ). A chest computed tomography transmission scan is used for attenuation correction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=see_link\">",
"     \"Attenuation artifact in SPECT radionuclide myocardial perfusion imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Selective A2A receptor agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The coronary vasodilation induced by adenosine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , which inhibits cellular reuptake of adenosine, are due to stimulation of the adenosine A2A receptors on vascular smooth muscle cells. These drugs also nonselectively activate the adenosine A1, A2B, and A3 receptors, which contributes to many of the common side effects associated with these drugs. Therefore, selective A2A receptor agonists have been developed in an effort to minimize the complications and discomfort from vasodilator stress testing. These agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    , binodenoson and apadenoson.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Regadenoson",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     Regadenoson",
"    </a>",
"    is a selective A2A receptor agonist that was FDA approved for use in rMPI in April 2008. It produces hyperemia with rapid onset (30 seconds) for a longer period (approximately two to five minutes) than adenosine, which permits more convenient administration (injection over 10 seconds). The prefilled single dose (0.4 mg) injection is likely to facilitate its use and reduce errors due to dose calculations. The half life for regadenoson has an initial intravenous phase of 2 minutes and a longer intermediate phase of 30 minutes.",
"   </p>",
"   <p>",
"    Data from two reports indicate noninferiority of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    as compared to adenosine for detection of ischemia. The ADVANCE-MPI 2 randomized double-blind multicenter trial compared regadenoson to adenosine in 784 patients at 54 sites [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/40\">",
"     40",
"    </a>",
"    ]. Regadenoson had similar efficacy to adenosine for detection of reversible perfusion defects. An analysis of the combined data of 1871 patients in the ADVANCE-MPI 1 and 2 randomized trials also demonstrated noninferiority for regadenoson relative to adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/41\">",
"     41",
"    </a>",
"    ]. Regadenoson induced perfusion defects correlated closely with adenosine induced defects in the ADVANCE-MPI 2 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/40\">",
"     40",
"    </a>",
"    ]. In both reports, regadenoson was associated with decreased overall symptom score (which included flushing, chest pain, and dyspnea.) However, regadenoson was more commonly associated with headache [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/26,41\">",
"     26,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     Regadenoson",
"    </a>",
"    has not been studied using cardiac PET perfusion imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h4\">",
"     Study protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     Regadenoson",
"    </a>",
"    0.4 mg in a 5 mL solution is infused over approximately 10 seconds into a peripheral vein using a 22-gauge or larger catheter or needle. A 5 mL saline flush should be immediately infused after the regadenoson injection to ensure appropriate drug delivery. The rMPI agent is infused 10 to 20 seconds after the saline flush and can. The radionuclide may be injected directly into the same catheter as regadenoson [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    may be injected during exercise in patients that are unable to achieve the desired work-load. The RegEx trial was a randomized, double-blind pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise in patients undergoing rMPI. The study found that combining regadenoson with low-level exercise is feasible, well tolerated, and associated with fewer side effects compared to adenosine alone [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Binodenoson",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binodenoson is a selective A2A adenosine receptor agonist that produces a similar degree of hyperemia to adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/43\">",
"     43",
"    </a>",
"    ]. It is currently investigational and has been evaluated in phase 3 studies. In a pilot trial in which 226 patients were treated with different doses of binodenoson and 226 were treated with adenosine, binodenoson produced very good to excellent agreement with adenosine in terms of the extent and severity of reversible perfusion defects, with the closest correlation noted with a 1.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    bolus [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/44\">",
"     44",
"    </a>",
"    ]. Like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    , this agent has a significant reduction in the incidence and severity of subjective side effects when compared to adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Apadenoson",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apadenoson is another A2A agonist that has demonstrated hyperemic responses similar to adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/45\">",
"     45",
"    </a>",
"    ] with, data suggests, fewer side effects. This agent is currently in phase 3 evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Comparison and vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are equally effective in increasing coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/12,46,47\">",
"     12,46,47",
"    </a>",
"    ], although individual subjects have substantial variations in responses to these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/16\">",
"     16",
"    </a>",
"    ]. When compared to dipyridamole, adenosine results in slightly greater systemic vasodilation, higher peak heart rate, and more frequent side effects, including AV block (",
"    <a class=\"graphic graphic_table graphicRef77326 \" href=\"UTD.htm?8/47/8957\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/48\">",
"     48",
"    </a>",
"    ]. However, because dipyridamole has a longer half-life, side effects last longer and more often require reversal with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    than with adenosine [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/48\">",
"     48",
"    </a>",
"    ]. On the other hand, the longer half-life of dipyridamole allows any level of supplemental exercise during combined vasodilator with exercise protocols. Exercise capacity data from combined vasodilator with exercise stress rMPI further risk stratify patients for future cardiac events [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Study protocol'",
"    </a>",
"    above.) When compared to adenosine, regadenoson offers fewer side effects including rhythm and conduction abnormalities.",
"   </p>",
"   <p>",
"    There is variability in the reported sensitivity and specificity for CAD diagnosis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    and adenosine depending upon the definition of CAD and the prevalence of disease in the population studied. In general, both agents have a comparable sensitivity and specificity of 81 to 91 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, adenosine may detect more ischemic segments and is often preferred by the patient, primarily because of the short duration of side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In a phase 3 trial",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    was shown to provide diagnostic information comparable to a standard adenosine infusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Addition of exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of low-level treadmill exercise during vasodilator stress test has added value. Protocols that include either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    or adenosine administration during exercise are safe, effective and yield important clinical information [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/52-54\">",
"     52-54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Example protocols:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upon completion of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      infusion, the patient may exercise at Bruce protocol Stage 1 (10 percent grade at 2.7",
"      <span class=\"nowrap\">",
"       km/h)",
"      </span>",
"      for as long as the patient can tolerate. The radiotracer is injected two minutes prior to exercise termination.",
"     </li>",
"     <li>",
"      During low level exercise at Bruce Stage 1 (10 percent grade at 2.7",
"      <span class=\"nowrap\">",
"       km/h)",
"      </span>",
"      adenosine is infused via protocol as described above. This will decrease side effects from adenosine and improve image quality by eliminating hepatic and gut uptake.",
"     </li>",
"     <li>",
"      A protocol for exercise with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      has also been proposed, although data are limited. During low low-level exercise regadenoson is injected with bolus intravenous injection of 400 mcg at 1.5 minutes and Tc99m sestamibi at two minutes.",
"     </li>",
"     <li>",
"      A prospective study is underway for patients that are unable to achieve maximum stress during regular exercise stress in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      is used as a back-up agent. The Ex-Lex study is currently under review [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, patients with left bundle branch block or right ventricular pacing undergoing pharmacologic stress should NOT undergo adjunctive low-level stress since increasing the heart rate of these patients may cause artifactual findings on rMPI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=see_link\">",
"     \"Stress testing in patients with left bundle branch block or a paced ventricular rhythm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     VASODILATOR SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Contraindications to vasodilators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are contraindicated in patients with hypotension (since these drugs lower the blood pressure), sick sinus syndrome, high degree atrioventricular (AV) block, and in patients receiving oral dipyridamole therapy. There is an increased risk for ischemic events in patients with an acute coronary syndrome, and stress imaging with vasodilators should be avoided in these settings, or if necessary, used cautiously [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another concern is bronchospastic airway disease since these drugs stimulate A2B receptors, which cause bronchospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/57\">",
"     57",
"    </a>",
"    ]. This issue was addressed in a report of 20 patients with severe chronic obstructive pulmonary disease (COPD) undergoing cardiac risk assessment prior to lung volume reduction surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/58\">",
"     58",
"    </a>",
"    ]. After the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    , 45 percent developed intolerable dyspnea, requiring intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    ; this was associated with a mean decrease in FEV1 of 15 percent from baseline.",
"   </p>",
"   <p>",
"    Thus, adenosine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    should generally not be used in patients with pronounced bronchospastic airway disease, even though this side effect may be promptly reversed by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"     aminophylline",
"    </a>",
"    . It has been suggested that the administration of aminophylline (50 mg by slow intravenous injection) after the injection of thallium may permit the use of dipyridamole without an increased incidence of adverse effects or interference with interpretation of the test [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/59\">",
"     59",
"    </a>",
"    ]. Moreover, since technetium-based tracers have minimal redistribution, administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    three minutes or more after the tracer is injected should not interfere with the imaging results.",
"   </p>",
"   <p>",
"    Preliminary data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    administration may be tolerated in patients with mild or moderate reactive airway disease. Small randomized double-blind studies of patients with mild or moderate asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/60\">",
"     60",
"    </a>",
"    ] and patients with moderate or severe chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/61\">",
"     61",
"    </a>",
"    ] found that regadenoson was well tolerated with no significant differences in FEV1 compared to placebo. However, larger trials are needed to validate this.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenosine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"     regadenoson",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    are safe in appropriately selected patients, including elderly adults (age &gt;75 years) (",
"    <a class=\"graphic graphic_table graphicRef77326 \" href=\"UTD.htm?8/47/8957\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/23,56,62-67\">",
"     23,56,62-67",
"    </a>",
"    ]. Patients typically experience a 10 percent decrease in blood pressure and a 15 percent increase in heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adenosine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinically important adverse events are uncommon with adenosine [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/23,63,68\">",
"       23,63,68",
"      </a>",
"      ]. In a registry report of 9256 consecutive patients, the most frequent were second degree AV block (4.1 percent), hypotension (1.8 percent), bradycardia (0.2 percent), third degree AV block (0.8 percent), and bronchospasm (0.1 percent); there were no deaths [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/63\">",
"       63",
"      </a>",
"      ]. All these side effects resolved spontaneously and rapidly with a reduction in the adenosine dose [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, minor side effects occurred in 81 percent of patients, with the most common being flushing, nausea, chest pain, dyspnea, and headache (",
"      <a class=\"graphic graphic_table graphicRef77326 \" href=\"UTD.htm?8/47/8957\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/63\">",
"       63",
"      </a>",
"      ]. These side effects are rapidly reversed by terminating the infusion or by administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      , which was required in 0.8 percent of patients.",
"     </li>",
"     <li>",
"      Atrial fibrillation has been reported in patients (with and without a history of atrial fibrillation) undergoing myocardial perfusion imaging with adenosine infusion, typically beginning during the adenosine infusion and persisting for up to six hours before spontaneously resolving [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       Regadenoson",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Clinically important adverse events are uncommon with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      . The presence of conduction abnormalities occurs less frequent in regadenoson when compared to adenosine. Most reactions resolve within 30 minutes.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"       Aminophylline",
"      </a>",
"      50 to 250 mg by slow intravenous injection (50 to 100 mg over 30 to 60 seconds) may be considered to attenuate severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      persistent adverse reactions to regadenoson [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The most common side effects for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      is shortness of breath, headache and flushing however as compared to adenosine, a prespecified tolerability comparison between the two agents showed significant lower symptoms with regadenoson when compared to adenosine [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       Dipyridamole",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      With appropriate use, serious",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      -induced adverse events are rare. In a report of over 73,000 patients, the incidence (per 10,000) of nonfatal myocardial infarction was 1.8, cardiac death rate 1.0, sustained ventricular tachycardia 0.8, and transient ischemic attack 1.2; these values were comparable to those with exercise stress testing [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As with adenosine, less serious symptoms are common with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      . This was illustrated in a review of almost 4000 studies in which the major side effects were chest pain (20 percent, most without ST segment changes), headache (12 percent), and dizziness (12 percent) (",
"      <a class=\"graphic graphic_table graphicRef77326 \" href=\"UTD.htm?8/47/8957\">",
"       table 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/5/10330/abstract/56\">",
"       56",
"      </a>",
"      ]. Parenteral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14648?source=see_link\">",
"       aminophylline",
"      </a>",
"      was required in 11.6 percent of patients (compared to 0.8 percent with adenosine 62) and terminated the symptoms in virtually all patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interactions between medications or diet and vasodilator stress agents is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19946?source=see_link\">",
"     \"Impact of medications and methylxanthines on stress testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A substantial proportion of patients referred for stress rMPI cannot exercise adequately and are candidates for pharmacologic stress test. Vasodilator stress MPI with adenosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      represents the preferred choice of pharmacologic stress and should be combined with exercise whenever possible. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of stress method'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      produce coronary vasodilation and, in the presence of significant coronary stenosis, they induce heterogeneous myocardial blood flow due to differences in coronary flow reserve. The heterogeneity of myocardial blood flow during hyperemia is detectable with a perfusion tracer and SPECT or PET imaging. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Mechanism of vasodilator stress'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adenosine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/38/23140?source=see_link\">",
"       regadenoson",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      are generally safe in appropriately selected patients. These agents are contraindicated in patients with AV block (except dipyridamole) or reactive airway disease. Preliminary data suggest that regadenoson may be tolerated by patients with mild to moderate reactive airway disease. However large trial data are not available for regadenoson. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Vasodilator safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are unable to exercise and have contraindications to vasodilators,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      is currently recommended as the stress agent in conjunction with either echocardiography or radionuclide myocardial perfusion imaging. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Choice of stress method'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=see_link&amp;anchor=H18#H18\">",
"       \"Stress echocardiography in the diagnosis and prognosis of coronary heart disease\", section on 'Dobutamine stress echocardiography'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=see_link\">",
"       \"Dobutamine stress radionuclide myocardial perfusion imaging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Both SPECT and PET imaging provide useful diagnostic and prognostic information during pharmacologic stress test. However, PET is preferable in patients with prior equivocal SPECT results and, possibly, in patients with obesity or established CHD. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Choice of isotope'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/1\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al. ACC/AHA 2002 guideline update for the management of patients with chronic stable angina--summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003; 41:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/2\">",
"      Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/3\">",
"      Gibbons RJ, Balady GJ, Beasley JW, et al. ACC/AHA Guidelines for Exercise Testing. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997; 30:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/4\">",
"      Iskandrian AS, Heo J, Kong B, Lyons E. Effect of exercise level on the ability of thallium-201 tomographic imaging in detecting coronary artery disease: analysis of 461 patients. J Am Coll Cardiol 1989; 14:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/5\">",
"      Heller GV, Ahmed I, Tilkemeier PL, et al. Influence of exercise intensity on the presence, distribution, and size of thallium-201 defects. Am Heart J 1992; 123:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/6\">",
"      Navare SM, Katten D, Johnson LL, et al. Risk stratification with electrocardiographic-gated dobutamine stress technetium-99m sestamibi single-photon emission tomographic imaging: value of heart rate response and assessment of left ventricular function. J Am Coll Cardiol 2006; 47:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/7\">",
"      Zoghbi GJ, Htay T, Aqel R, et al. Effect of caffeine on ischemia detection by adenosine single-photon emission computed tomography perfusion imaging. J Am Coll Cardiol 2006; 47:2296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/8\">",
"      Yoshinaga K, Chow BJ, Williams K, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol 2006; 48:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/9\">",
"      Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006; 13:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/10\">",
"      Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). J Am Coll Cardiol 2003; 42:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/11\">",
"      Chow BJ, Ananthasubramaniam K, dekemp RA, et al. Comparison of treadmill exercise versus dipyridamole stress with myocardial perfusion imaging using rubidium-82 positron emission tomography. J Am Coll Cardiol 2005; 45:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/12\">",
"      Chan SY, Brunken RC, Czernin J, et al. Comparison of maximal myocardial blood flow during adenosine infusion with that of intravenous dipyridamole in normal men. J Am Coll Cardiol 1992; 20:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/13\">",
"      Wilson RF, Wyche K, Christensen BV, et al. Effects of adenosine on human coronary arterial circulation. Circulation 1990; 82:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/14\">",
"      Trochu JN, Zhao G, Post H, et al. Selective A2A adenosine receptor agonist as a coronary vasodilator in conscious dogs: potential for use in myocardial perfusion imaging. J Cardiovasc Pharmacol 2003; 41:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/15\">",
"      Voudris V, Manginas A, Vassilikos V, et al. Coronary flow velocity changes after intravenous dipyridamole infusion: measurements using intravascular Doppler guide wire. A documentation of flow inhomogeneity. J Am Coll Cardiol 1996; 27:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/16\">",
"      Gould KL, Kirkeeide RL, Buchi M. Coronary flow reserve as a physiologic measure of stenosis severity. J Am Coll Cardiol 1990; 15:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/17\">",
"      Klocke FJ. Cognition in the era of technology: \"seeing the shades of gray\". J Am Coll Cardiol 1990; 16:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/18\">",
"      Chambers CE, Brown KA. Dipyridamole-induced ST segment depression during thallium-201 imaging in patients with coronary artery disease: angiographic and hemodynamic determinants. J Am Coll Cardiol 1988; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/19\">",
"      Nishimura S, Kimball KT, Mahmarian JJ, Verani MS. Angiographic and hemodynamic determinants of myocardial ischemia during adenosine thallium-201 scintigraphy in coronary artery disease. Circulation 1993; 87:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/20\">",
"      Akinboboye OO, Idris O, Chou RL, et al. Absolute quantitation of coronary steal induced by intravenous dipyridamole. J Am Coll Cardiol 2001; 37:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/21\">",
"      Thomas GS, Miyamoto MI. Should simultaneous exercise become the standard for adenosine myocardial perfusion imaging? Am J Cardiol 2004; 94:3D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/22\">",
"      Hays JT, Mahmarian JJ, Cochran AJ, Verani MS. Dobutamine thallium-201 tomography for evaluating patients with suspected coronary artery disease unable to undergo exercise or vasodilator pharmacologic stress testing. J Am Coll Cardiol 1993; 21:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/23\">",
"      Abreu A, Mahmarian JJ, Nishimura S, et al. Tolerance and safety of pharmacologic coronary vasodilation with adenosine in association with thallium-201 scintigraphy in patients with suspected coronary artery disease. J Am Coll Cardiol 1991; 18:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/24\">",
"      Cosmai EM, Heller GV. The clinical importance of electrocardiographic changes during pharmacologic stress testing with radionuclide myocardial perfusion imaging. J Nucl Cardiol 2005; 12:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/25\">",
"      Sylv&eacute;n C, Beermann B, Jonzon B, Brandt R. Angina pectoris-like pain provoked by intravenous adenosine in healthy volunteers. Br Med J (Clin Res Ed) 1986; 293:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/26\">",
"      Iskandrian AE, Bateman TM, Belardinelli L, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 2007; 14:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/27\">",
"      Marcassa C, Galli M, Baroffio C, et al. Transient left ventricular dilation at quantitative stress-rest sestamibi tomography: clinical, electrocardiographic, and angiographic correlates. J Nucl Cardiol 1999; 6:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/28\">",
"      Chouraqui P, Rodrigues EA, Berman DS, Maddahi J. Significance of dipyridamole-induced transient dilation of the left ventricle during thallium-201 scintigraphy in suspected coronary artery disease. Am J Cardiol 1990; 66:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/29\">",
"      Iskandrian AS, Heo J, Nguyen T, et al. Left ventricular dilatation and pulmonary thallium uptake after single-photon emission computer tomography using thallium-201 during adenosine-induced coronary hyperemia. Am J Cardiol 1990; 66:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/30\">",
"      McClellan JR, Travin MI, Herman SD, et al. Prognostic importance of scintigraphic left ventricular cavity dilation during intravenous dipyridamole technetium-99m sestamibi myocardial tomographic imaging in predicting coronary events. Am J Cardiol 1997; 79:600.",
"     </a>",
"    </li>",
"    <li>",
"     2009 ASNC imaging guidelines for nuclear cardiology procedures, section on \"Stress protocols and tracers\" file://www.asnc.org/imageuploads/ImagingGuidelinesStressProtocols021109.pdf (Accessed on September 27, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/32\">",
"      Henzlova MJ, Cerqueira MD, Mahmarian JJ, et al. Stress protocols and tracers. J Nucl Cardiol 2006; 13:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/33\">",
"      Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 1997; 79:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/34\">",
"      Iskandrian AE, Heo J. Myocardial perfusion imaging during adenosine-induced coronary hyperemia. Am J Cardiol 1997; 79:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/35\">",
"      O'Keefe JH Jr, Bateman TM, Handlin LR, Barnhart CS. Four- versus 6-minute infusion protocol for adenosine thallium-201 single photon emission computed tomography imaging. Am Heart J 1995; 129:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/36\">",
"      Knabb RM, Gidday JM, Ely SW, et al. Effects of dipyridamole on myocardial adenosine and active hyperemia. Am J Physiol 1984; 247:H804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/37\">",
"      McLaughlin DP, Beller GA, Linden J, et al. Hemodynamic and metabolic correlates of dipyridamole-induced myocardial thallium-201 perfusion abnormalities in multivessel coronary artery disease. Am J Cardiol 1994; 73:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/38\">",
"      Ahlberg AW, Baghdasarian SB, Athar H, et al. Symptom-limited exercise combined with dipyridamole stress: prognostic value in assessment of known or suspected coronary artery disease by use of gated SPECT imaging. J Nucl Cardiol 2008; 15:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/39\">",
"      Bateman TM. Cardiac positron emission tomography and the role of adenosine pharmacologic stress. Am J Cardiol 2004; 94:19D.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/40\">",
"      Mahmarian JJ, Cerqueira MD, Iskandrian AE, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial. JACC Cardiovasc Imaging 2009; 2:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/41\">",
"      Cerqueira MD, Nguyen P, Staehr P, et al. Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 2008; 1:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/42\">",
"      Thomas GS, Thompson RC, Miyamoto MI, et al. The RegEx trial: a randomized, double-blind, placebo- and active-controlled pilot study combining regadenoson, a selective A(2A) adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 2009; 16:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/43\">",
"      Hodgson JM, Dib N, Kern MJ, et al. Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol 2007; 99:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/44\">",
"      Udelson JE, Heller GV, Wackers FJ, et al. Randomized, controlled dose-ranging study of the selective adenosine A2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging. Circulation 2004; 109:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/45\">",
"      Glover DK, Ruiz M, Takehana K, et al. Pharmacological stress myocardial perfusion imaging with the potent and selective A(2A) adenosine receptor agonists ATL193 and ATL146e administered by either intravenous infusion or bolus injection. Circulation 2001; 104:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/46\">",
"      Uren NG, Melin JA, De Bruyne B, et al. Relation between myocardial blood flow and the severity of coronary-artery stenosis. N Engl J Med 1994; 330:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/47\">",
"      Rossen JD, Quillen JE, Lopez AG, et al. Comparison of coronary vasodilation with intravenous dipyridamole and adenosine. J Am Coll Cardiol 1991; 18:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/48\">",
"      Johnston DL, Daley JR, Hodge DO, et al. Hemodynamic responses and adverse effects associated with adenosine and dipyridamole pharmacologic stress testing: a comparison in 2,000 patients. Mayo Clin Proc 1995; 70:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/49\">",
"      Geleijnse ML, Elhendy A, Fioretti PM, Roelandt JR. Dobutamine stress myocardial perfusion imaging. J Am Coll Cardiol 2000; 36:2017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/50\">",
"      Leppo JA. Comparison of pharmacologic stress agents. J Nucl Cardiol 1996; 3:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/51\">",
"      Taillefer R, Amyot R, Turpin S, et al. Comparison between dipyridamole and adenosine as pharmacologic coronary vasodilators in detection of coronary artery disease with thallium 201 imaging. J Nucl Cardiol 1996; 3:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/52\">",
"      Candell-Riera J, Santana-Boado C, Castell-Conesa J, et al. Simultaneous dipyridamole/maximal subjective exercise with 99mTc-MIBI SPECT: improved diagnostic yield in coronary artery disease. J Am Coll Cardiol 1997; 29:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/53\">",
"      Holly TA, Satran A, Bromet DS, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nucl Cardiol 2003; 10:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/54\">",
"      Vitola JV, Brambatti JC, Caligaris F, et al. Exercise supplementation to dipyridamole prevents hypotension, improves electrocardiogram sensitivity, and increases heart-to-liver activity ratio on Tc-99m sestamibi imaging. J Nucl Cardiol 2001; 8:652.",
"     </a>",
"    </li>",
"    <li>",
"     United States: Food and Drug, Administration. Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging. 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/56\">",
"      Ranhosky A, Kempthorne-Rawson J. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Intravenous Dipyridamole Thallium Imaging Study Group. Circulation 1990; 81:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/57\">",
"      Lette J, Cerino M, Laverdiere M, et al. Severe bronchospasm followed by respiratory arrest during thallium-dipyridamole imaging. Chest 1989; 95:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/58\">",
"      Thurnheer R, Laube I, Kaufmann PA, et al. Practicability and safety of dipyridamole cardiac imaging in patients with severe chronic obstructive pulmonary disease. Eur J Nucl Med 1999; 26:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/59\">",
"      Shaffer J, Simbartl L, Render ML, et al. Patients with stable chronic obstructive pulmonary disease can safely undergo intravenous dipyridamole thallium-201 imaging. Am Heart J 1998; 136:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/60\">",
"      Leaker BR, O'Connor B, Hansel TT, et al. Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 2008; 15:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/61\">",
"      Thomas GS, Tammelin BR, Schiffman GL, et al. Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 2008; 15:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/62\">",
"      Lette J, Tatum JL, Fraser S, et al. Safety of dipyridamole testing in 73,806 patients: the Multicenter Dipyridamole Safety Study. J Nucl Cardiol 1995; 2:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/63\">",
"      Cerqueira MD, Verani MS, Schwaiger M, et al. Safety profile of adenosine stress perfusion imaging: results from the Adenoscan Multicenter Trial Registry. J Am Coll Cardiol 1994; 23:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/64\">",
"      Verani MS, Mahmarian JJ, Hixson JB, et al. Diagnosis of coronary artery disease by controlled coronary vasodilation with adenosine and thallium-201 scintigraphy in patients unable to exercise. Circulation 1990; 82:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/65\">",
"      Mathias W Jr, Arruda A, Santos FC, et al. Safety of dobutamine-atropine stress echocardiography: A prospective experience of 4,033 consecutive studies. J Am Soc Echocardiogr 1999; 12:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/66\">",
"      Hashimoto A, Palmar EL, Scott JA, et al. Complications of exercise and pharmacologic stress tests: differences in younger and elderly patients. J Nucl Cardiol 1999; 6:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/67\">",
"      Mahmarian JJ, Verani MS. Myocardial perfusion imaging during pharmacologic stress testing. Cardiol Clin 1994; 12:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/68\">",
"      Alkoutami GS, Reeves WC, Movahed A. The frequency of atrioventricular block during adenosine stress testing in young, middle-aged, young-old, and old-old adults. Am J Geriatr Cardiol 2001; 10:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/69\">",
"      Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997; 127:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/5/10330/abstract/70\">",
"      Glatter KA, Cheng J, Dorostkar P, et al. Electrophysiologic effects of adenosine in patients with supraventricular tachycardia. Circulation 1999; 99:1034.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5328 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-3DC0084E0B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10330=[""].join("\n");
var outline_f10_5_10330=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H26\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TEST OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Choice of stress method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Choice of isotope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      MECHANISM OF VASODILATOR STRESS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Relative flow differences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coronary steal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - ST segment depression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Left ventricular dilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      VASODILATOR AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adenosine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Study protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Dipyridamole",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Study protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Selective A2A receptor agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Regadenoson",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Study protocol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Binodenoson",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Apadenoson",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Comparison and vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Addition of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      VASODILATOR SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Contraindications to vasodilators",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/5328\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5328|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?26/46/27363\" title=\"algorithm 1\">",
"      Algorithm for choosing the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5328|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/61/980\" title=\"diagnostic image 1\">",
"      Transient dilation pharm stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5328|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/26/35247\" title=\"figure 1\">",
"      Adenosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/2/30766\" title=\"figure 2\">",
"      Protocol adenosine stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/63/24573\" title=\"figure 3\">",
"      Protocol dipyridamole stress",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/0/37901\" title=\"figure 4\">",
"      Gated PET perfusion protocol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/5328|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/42/3757\" title=\"table 1\">",
"      Comparison pharm stress agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/47/8957\" title=\"table 2\">",
"      Side effect pharm stress agents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=related_link\">",
"      Attenuation artifact in SPECT radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=related_link\">",
"      Basic properties of myocardial perfusion agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8759?source=related_link\">",
"      Clinical syndromes of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/1/8216?source=related_link\">",
"      Coronary collateral circulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/9/42134?source=related_link\">",
"      Dobutamine stress radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24970?source=related_link\">",
"      Exercise radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19946?source=related_link\">",
"      Impact of medications and methylxanthines on stress testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/30/44520?source=related_link\">",
"      Selecting the optimal cardiac stress test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27466?source=related_link\">",
"      Stress echocardiography in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26521?source=related_link\">",
"      Stress testing for the diagnosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/4/28743?source=related_link\">",
"      Stress testing in patients with left bundle branch block or a paced ventricular rhythm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/58/2986?source=related_link\">",
"      Stress testing to determine prognosis and management of patients with known or suspected coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43081?source=related_link\">",
"      Vasodilator stress radionuclide myocardial perfusion imaging in the diagnosis and prognosis of coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_5_10331="Examination findings in opioid poisoning";
var content_f10_5_10331=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physical examination findings of opioid poisoning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Vital Signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Heart rate decreased or unchanged",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Blood pressure decreased or unchanged",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Respiratory rate decreased",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Temperature decreased or unchanged",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Gastrointestinal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Decreased bowel sounds",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Neurological",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sedation or coma",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Seizure (Meperidine, Propoxyphene, Tramadol, or as a result of hypoxia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Ophthalmologic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Miosis",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10331=[""].join("\n");
var outline_f10_5_10331=null;
var title_f10_5_10332="CSHCN transition resources";
var content_f10_5_10332=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59408&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Resources for addressing the transition to adulthood for children with special health care needs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Healthy and Ready to Work National Resource Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.hrtw.org\" target=\"_blank\">",
"         www.hrtw.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Health Care Transition Center",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.gottransition.org/families-resources\" target=\"_blank\">",
"         www.gottransition.org/families-resources",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Adolescent Health Transition Project",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://depts.washington.edu/healthtr\" target=\"_blank\">",
"         depts.washington.edu/healthtr",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Center on Secondary Education and Transition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.ncset.org\" target=\"_blank\">",
"         www.ncset.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Transition Network - Institute on Community Integration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://ici2.umn.edu/ntn\" target=\"_blank\">",
"         ici2.umn.edu/ntn",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        National Collaborative on Workforce and Disability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.ncwd-youth.info\" target=\"_blank\">",
"         www.ncwd-youth.info",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        TelAbility: Enhancing the lives of children with disabilities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.telability.org\" target=\"_blank\">",
"         www.telability.org",
"        </a>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        The Youthhood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <a href=\"file://www.youthhood.org/index.asp\" target=\"_blank\">",
"         www.youthhood.org/index.asp",
"        </a>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Levey EB, Murphy NA. Addressing transition to adulthood with special needs patients. AAP News September 2005; 26:19.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10332=[""].join("\n");
var outline_f10_5_10332=null;
var title_f10_5_10333="Screening tests for CRC";
var content_f10_5_10333=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F71954%7EPC%2F63768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F71954%7EPC%2F63768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the characteristics of screening tests for colorectal cancer",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Screening test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test performance (sensitivity, specificity)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Complexity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential effectiveness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Evidence of effectiveness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Screening test risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal occult blood test",
"       </td>",
"       <td>",
"        Intermediate for cancers, low for polyps",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"       <td>",
"        Strongest",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fecal immunochemical test for hemoglobin",
"       </td>",
"       <td>",
"        Intermediate for cancers, low for polyps",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Lowest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Flexible sigmoidoscopy",
"       </td>",
"       <td>",
"        High for up to half of the colon",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FOBT + flexible sigmoidoscopy",
"       </td>",
"       <td>",
"        Same as flexible sigmoidoscopy and FOBT",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Double contrast barium enema",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Highest",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Computed tomographic colonography",
"       </td>",
"       <td>",
"        High (similar to colonoscopy)",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Weakest",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     The costs of the screening tests themselves, also an important characteristic, vary, but the costs of the screening strategies (lifetime programs of screening and follow-up of abnormal test results) are comparable. Complexity involves patient preparation, inconvenience, facilities and equipment needed, and patient discomfort.",
"    </div>",
"    <div class=\"reference\">",
"     Data updated according to joint multi-society guidelines 2008. Adapted from Winawer, SW, Fletcher, RH, Mille, L, et al. AGA guidelines: Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology 1997; 112: 594.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major complication rates of screening tests",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Screening test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perforation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barium enema",
"       </td>",
"       <td>",
"        1/10,000",
"       </td>",
"       <td>",
"        1/50,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sigmoidoscopy",
"       </td>",
"       <td>",
"        9/10,000",
"       </td>",
"       <td>",
"        1/18,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colonoscopy*",
"       </td>",
"       <td>",
"        2/1,000",
"       </td>",
"       <td>",
"        1/10,000",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Major complications are more frequent if polypectomy is performed.",
"    </div>",
"    <div class=\"reference\">",
"     Barium enema data adapted from Winawer, SJ, Fletcher, RH, Miller, L, et al. Gastroenterology 1997; 112:594. Sigmoidoscopy and colonoscopy data adapted from Gatto, NM, Frucht, H, Sundararajan, V, et al. J Natl Cancer Inst 2003; 95:230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10333=[""].join("\n");
var outline_f10_5_10333=null;
var title_f10_5_10334="Dual isotope MPI prognosis CHD";
var content_f10_5_10334=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F53586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F53586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Dual-isotope MPI predicts prognosis in CHD",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 324px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relationship between the coronary risk as determined by the Duke treadmill score on exercise ECG testing, the findings on dual-isotope SPECT myocardial imaging (categorized as normal, mildly abnormal, or severely abnormal), and the \"hard\" event rate (myocardial infarction or death) at 1.5 years in 2200 consecutive patients with possible CHD. In this population at overall low risk for \"hard\" events (1.8 percent), dual isotope SPECT added incremental prognostic information to the Duke treadmill score. The event rates in the three Duke treadmill score groups were 0.9 percent in the 926 patients in low, 2.5 percent in the 1187 patients in intermediate, and 7.7 percent in the 90 patients in severe.",
"    <div class=\"footnotes\">",
"     * Statistically significant difference across scan results. The likelihood of severe abnormalities on MPI was much greater in those with a high Duke treadmill score (44 versus 6 and 14 percent in the low and intermediate groups).",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hachamovitch, R, Berman, S, Kiat, H, et al, Circulation 1996; 93:905.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10334=[""].join("\n");
var outline_f10_5_10334=null;
var title_f10_5_10335="Algorithm for IHC in assessment of HER2 status";
var content_f10_5_10335=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Algorithm for IHC in assessment of HER2 status",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 435px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolff AC, Hammond EH, Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Onc 2007; 25:1. Copyright &copy; 2007 the American Society of Clinical Oncology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_5_10335=[""].join("\n");
var outline_f10_5_10335=null;
